Original Article
Risperidone in Children with Autism and Serious Behavioral Problems
N Engl J Med 2002; 347:314-321August 1, 2002
- Abstract
Background
Atypical antipsychotic agents, which block postsynaptic dopamine and serotonin receptors, have advantages over traditional antipsychotic medications in the treatment of adults with schizophrenia and may be beneficial in children with autistic disorder who have serious behavioral disturbances. However, data on the safety and efficacy of atypical antipsychotic agents in children are limited.
Methods
We conducted a multisite, randomized, double-blind trial of risperidone as compared with placebo for the treatment of autistic disorder accompanied by severe tantrums, aggression, or self-injurious behavior in children 5 to 17 years old. The primary outcome measures were the score on the Irritability subscale of the Aberrant Behavior Checklist and the rating on the Clinical Global Impressions — Improvement (CGI-I) scale at eight weeks.
Results
A total of 101 children (82 boys and 19 girls; mean [±SD] age, 8.8±2.7 years) were randomly assigned to receive risperidone (49 children) or placebo (52). Treatment with risperidone for eight weeks (dose range, 0.5 to 3.5 mg per day) resulted in a 56.9 percent reduction in the Irritability score, as compared with a 14.1 percent decrease in the placebo group (P<0.001). The rate of a positive response, defined as at least a 25 percent decrease in the Irritability score and a rating of much improved or very much improved on the CGI-I scale, was 69 percent in the risperidone group (34 of 49 children had a positive response) and 12 percent in the placebo group (6 of 52, P<0.001). Risperidone therapy was associated with an average weight gain of 2.7±2.9 kg, as compared with 0.8±2.2 kg with placebo (P<0.001). Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison). In two thirds of the children with a positive response to risperidone at eight weeks (23 of 34), the benefit was maintained at six months.
Conclusions
Risperidone was effective and well tolerated for the treatment of tantrums, aggression, or self-injurious behavior in children with autistic disorder. The short period of this trial limits inferences about adverse effects such as tardive dyskinesia.
Media in This Article
Figure 2
Percentage of Children with a Rating of Much Improved or Very Much Improved on the Clinical Global Impressions — Improvement Scale during the Eight-Week Trial.Figure 1
Mean Scores for Irritability in the Risperidone and Placebo Groups during the Eight-Week Trial.Article Activity
- Article
Autism, a chronic condition that develops in early childhood, is characterized by a marked impairment in the ability to relate to others, delayed language, and restricted patterns of behavior. The disorder affects as many as 20 children per 10,000.1
In addition to core symptoms, children with autism frequently have serious behavioral disturbances, such as self-injurious behavior, aggression, and tantrums in response to routine environmental demands.2 These behavioral problems interfere with rehabilitative efforts and pose enormous challenges to parents and educators. Although behavior therapy may reduce aggression and self-injury, it tends to be highly individualized and has not been evaluated in randomized clinical trials.3 Attempts to treat autism with several medications in various chemical classes have had limited success.4 To date, only haloperidol, a potent postsynaptic dopamine-receptor antagonist, has been shown in more than one study to be superior to placebo for the treatment of serious behavioral problems.5,6 However, many clinicians avoid using haloperidol in children because of concern about its short- and long-term side effects.7
Unlike haloperidol, atypical antipsychotic agents block postsynaptic serotonin receptors. The affinity of these agents for serotonin receptors may enhance their efficacy and provide protection against extrapyramidal symptoms.8 Alternatively, atypical antipsychotic agents may be more easily displaced by endogenous dopamine, which reduces the risk of neurologic side effects.9 Given the lower frequency of extrapyramidal symptoms with atypical antipsychotic agents and their reported efficacy for treating both positive and negative symptoms in adults with schizophrenia, there is great interest in the question of whether these agents are beneficial in children with developmental disorders.10 To date, only one placebo-controlled study of risperidone in adults with autism and a handful of open-label studies in children with pervasive developmental disorders have been reported.11-13 We conducted a multisite study to evaluate the efficacy and safety of risperidone in children with autism accompanied by serious behavioral disturbances.
Methods
Subjects
The first phase of the study was an eight-week, double-blind, randomized, placebo-controlled trial of risperidone (Risperdal, Janssen) conducted by the Autism Network of the Research Units on Pediatric Psychopharmacology between June 1999 and April 2001. At the end of the double-blind phase, children in the placebo group who had had no improvement in their behavior were offered open-label treatment with risperidone, as were children in the risperidone group who met the predetermined criteria for a positive response. Open-label treatment was given for four months, followed by a two-month, placebo-controlled discontinuation phase, as described elsewhere.14 The study sites included the University of California at Los Angeles, Ohio State University, Indiana University, Yale University, and the Kennedy Krieger Institute at Johns Hopkins University. The protocol was approved by the institutional review board at each site, and written informed consent was obtained from a parent or guardian before enrollment. Safety and adherence to the protocol were monitored through weekly conference calls, annual site visits by investigators at the coordinating center (Yale University), and quarterly reviews by the data and safety monitoring board convened by the National Institute of Mental Health.
All children met the criteria for autistic disorder described in the Diagnostic and Statistical Manual of Mental Disorders, fourth edition,15 with tantrums, aggression, self-injurious behavior, or a combination of these problems. Other enrollment criteria included an age of 5 to 17 years, a weight of at least 15 kg, and a mental age of at least 18 months. The children had to be free of serious medical disorders and of other psychiatric disorders requiring medication. We reviewed each child's past and current treatments for autism. In consultation with parents, children receiving a psychotropic drug that was deemed effective for the treatment of aggression, tantrums, or self-injurious behavior were excluded. Ineffective medications were gradually withdrawn, and a drug-free interval of 7 to 28 days, depending on the drug, was required before enrollment. Treatment with an anticonvulsant agent for seizure control was allowed if the dose had been unchanged for at least four weeks and if there had been no seizures for at least six months.
Base-Line Assessment and Outcome Measures
The diagnosis of autistic disorder was corroborated by the Autism Diagnostic Interview — Revised. This semistructured interview was administered by a clinician with special training and systematic review to ensure reliability.16 Screening also included intelligence testing; administration of the Vineland Adaptive Behavior Scales (the population mean [±SD] for each scale is 100±15; higher scores indicate more adaptive behavior)17; routine laboratory tests; electrocardiography; measurement of height, weight, and vital signs; medical history taking; and physical examination. The child's race was reported by the parent or primary caretaker. Clinically significant behavioral problems were defined by a rating of moderate or higher on the Clinical Global Impressions — Severity (CGI-S) scale, as determined by a clinician,18 and by a score of 18 or higher on the Irritability subscale of the Aberrant Behavior Checklist, as rated by the parent (or primary caretaker) and confirmed by a clinician. The 15-item Irritability subscale includes questions about aggression, self-injury, tantrums, agitation, and unstable mood on a scale of 0 to 45, with higher scores indicating greater severity. Data from studies of developmentally disabled children indicate that a score of 18 is 1.3 to 1.5 SD above the population mean, depending on the age and sex of the child.19,20 To exclude children whose symptoms might improve in response to nonspecific clinical contact, the children were reassessed at base line, 7 to 14 days after the initial assessment. Only children who met the inclusion criteria for the CGI-S scale (according to an experienced clinician) and the score on the Irritability subscale (based on the parent's or primary caretaker's rating) at base line as well as at the time of screening were eligible for randomization. The Irritability scores obtained at this second evaluation were used as base-line values.
Each child was seen weekly by two clinicians who were unaware of the treatment assignment: a primary clinician, who reviewed side effects and adjusted the dose of medication, and a clinical evaluator, who assessed the response to treatment. The primary outcome measures were the score at eight weeks on the Irritability subscale of the Aberrant Behavior Checklist, based on the parent's or primary caretaker's rating, and the rating on the Clinical Global Impressions — Improvement (CGI-I) scale, as determined by the clinical evaluator. Children who had at least a 25 percent reduction in the Irritability score and a rating of much improved or very much improved on the CGI-I scale were considered to have a positive response.
Other outcomes were scores on the other subscales of the Aberrant Behavior Checklist (Social Withdrawal, Stereotypy, Hyperactivity, and Inappropriate Speech), based on ratings by the parent or primary caretaker. At base line, the parent or primary caretaker was interviewed to identify the target symptoms and to rate compulsive behavior according to the Children's Yale–Brown Obsessive Compulsive Scale. These semistructured interviews were used in determining the score on the CGI-I scale at subsequent visits, as described in detail elsewhere.21
Medication Schedule
For children who weighed 20 to 45 kg, risperidone was given at an initial dose of 0.5 mg at bedtime and was increased to 0.5 mg twice daily on day 4. The dose was gradually increased in 0.5-mg increments to a maximum of 2.5 mg per day (1.0 mg in the morning and 1.5 mg at bedtime) by day 29. A slightly accelerated dose schedule was used for children who weighed more than 45 kg, with a maximal dose of 1.5 mg in the morning and 2.0 mg at bedtime. For children who weighed less than 20 kg, the initial dose was 0.25 mg per day. Scheduled dose increases could be delayed because of adverse effects or because of marked improvement at a lower dose. Dose reductions to manage side effects were allowed at any time, but there were no dose increases after day 29.
Monitoring for Safety
Laboratory tests, electrocardiographic studies, and physical examination were repeated at eight weeks; weight and vital signs were assessed weekly. At each visit, the primary clinician inquired about health problems, intercurrent illness, and concomitant medications and administered a 32-item questionnaire concerning energy level, muscle stiffness, motor restlessness, bowel and bladder habits, sleep, and appetite. Neurologic side effects were assessed weekly with the use of the Simpson–Angus scale22 and the Abnormal Involuntary Movement Scale.18 Adverse events noted as a result of any of these methods were documented with respect to severity, duration, management, and outcome.
Statistical Analysis
Data were analyzed according to the intention-to-treat principle. Statistical tests were two-tailed. P values of 0.05 or less were considered to indicate statistical significance, except for the analysis of adverse events (P<0.10) and analyses adjusted for multiple comparisons (the Bonferroni method). The biweekly scores on the Irritability subscale were analyzed with the use of mixed-effects linear models in which the study group and site were the fixed effects and the outcome and time were the random effects.23 The mixed-effects approach makes full use of available data and allowed us to combine subject-specific scores on the Irritability subscale in order to estimate the slope of the regression line for each group over time. A strong downward trend in Irritability scores in the risperidone group, as compared with the placebo group, would indicate a statistically significant interaction between treatment and time. Interactions with the site that were not significant were removed from the final model. The parameters of the mixed-effects model were estimated with the use of SAS Proc Mixed software.24
To compare our results with those of other trials and to estimate the likelihood of a response to risperidone in other patients with similar problems, we conducted two additional analyses. First, using our previously stated definition of a treatment response, we compared the rate of positive responses in each study group with the use of the chi-square test. Second, we calculated the size of the effect (the change from base line at eight weeks) for each scale of the Aberrant Behavior Checklist.
Differences in adverse events were tested by the chi-square test or Fisher's exact test when subgroups contained fewer than five children. Continuous variables were assessed with the use of the regression model described above.
Results
Base-Line Characteristics
Of the 270 children who were screened for the study, 112 did not meet the criteria for enrollment, the parents or guardians of 57 children declined participation. The remaining 101 children (82 boys and 19 girls) were enrolled and randomly assigned to receive risperidone (49 children) or placebo (52). We subsequently identified four children who did not meet the entry criteria because their Irritability subscale had fallen below the threshold of 18 at base line. An analysis of the Irritability data that excluded these four children had results that were virtually identical to those with the full sample. Thus, the intention-to-treat analysis included all 101 children.
The children ranged in age from 5 to 17 years (mean [±SD], 8.8±2.7); 87 percent (88 children) were prepubertal; 66 percent (67) were white, 11 percent (11) were black, 7 percent (7) were Hispanic, 8 percent (8) were Asian, and 8 percent (8) were members of other racial or ethnic groups; and 91 percent (92) lived at home with at least one parent. The two groups were similar at base line with respect to a range of demographic, developmental, and clinical characteristics, including mean scores on the Aberrant Behavior Checklist subscales, with the exception of the score on the Inappropriate-Speech subscale, which was higher in the placebo group than in the risperidone group (Table 1Table 1
Base-Line Characteristics of 101 Children Randomly Assigned to Receive Risperidone or Placebo.).Primary Outcome
Analysis of the scores on the Irritability subscale revealed a significant interaction between the study group and time (P<0.001) (Figure 1Figure 1
Mean Scores for Irritability in the Risperidone and Placebo Groups during the Eight-Week Trial.). After eight weeks of treatment, the risperidone group had a 56.9 percent decrease in the mean Irritability score (from 26.2±7.9 at base line to 11.3±7.4 at eight weeks), as compared with a 14.1 percent decrease in the placebo group (from 25.5±6.6 to 21.9±9.5, P<0.001) (Table 2Table 2
Scores on the Aberrant Behavior Checklist at Base Line and Eight Weeks.). The rate of a positive response (at least a 25 percent improvement in the score on the Irritability subscale and a rating of much improved or very much improved on the CGI-I scale) was 69 percent in the risperidone group (34 of the 49 children had a positive response) and 12 percent in the placebo group (6 of 52, P<0.001).These gains in the risperidone group were maintained for six months in 23 of the 34 children (68 percent) who had had positive responses in the double-blind phase of the study. Of the other 11 children who had positive responses with risperidone, 2 did not enter the extension phase of the study because the family moved and 2 because the parents decided to evaluate the children's behavior in the absence of medication. During the extension phase, the parents of two children decided to seek other treatment in addition to risperidone; four children were withdrawn because the treatment was no longer effective, and one child was withdrawn because of an unrelated medical problem.
Secondary Outcomes
Table 2 shows the mean base-line and end-point scores, as well as the effect size, for all the subscales of the Aberrant Behavior Checklist in each study group. After correction for multiple comparisons, there was a significant interaction between the study group and time for scores on the Stereotypy and Hyperactivity subscales, suggesting that risperidone improved behavior in these areas as well. Scores for Social Withdrawal and Inappropriate Speech did not differ significantly between the two groups (after Bonferroni correction).
The rate of improvement over time is shown in Figure 2Figure 2
Percentage of Children with a Rating of Much Improved or Very Much Improved on the Clinical Global Impressions — Improvement Scale during the Eight-Week Trial.. The proportion of children whose behavior was rated as much improved or very much improved on the CGI-I scale differed by 44 percent between the study groups at week 4 (P<0.001) and by 64 percent at week 8 (P<0.001).Medication Dose
The mean daily dose of risperidone during the final week of the study was 1.8±0.7 mg (range, 0.5 to 3.5). The mean dose of placebo dispensed was equivalent to 2.4±0.6 mg per day (range, 1.0 to 3.5; P<0.001).
Adverse Events
There was a significantly greater mean increase in weight in the risperidone group (2.7±2.9 kg) than in the placebo group (0.8±2.2 kg, P<0.001) (Table 3Table 3
Adverse Events Reported during the Eight-Week Trial.). The weight gain in the risperidone group was associated with a mild increase in appetite (in 49 percent of children) or a moderate increase in appetite (in 24 percent), as reported by the parent or primary caretaker (P=0.03 and P=0.01, respectively, for the comparison with the placebo group).Sixty different adverse events were recorded during the trial, 29 of which occurred in 5 percent or more of the children (Table 3). There were no serious adverse events in the risperidone group, and no children were withdrawn from the study because of an adverse event. Most adverse events were mild and self-limited. For example, 23 children (47 percent) in the risperidone group had mild fatigue, but only 6 (12 percent) had moderate fatigue. In most cases, the fatigue had subsided by week 6. Similarly, of the 24 children in the risperidone group described as drowsy by their parents or primary caretakers, 16 were considered to be mildly drowsy, and they were no longer drowsy by week 4.
Weekly assessment with the Abnormal Involuntary Movement Scale and the Simpson–Angus scale showed no extrapyramidal symptoms in either group. Parents or caretakers reported five neurologic side effects: tremor, dyskinesia, rigidity, akathisia, and difficulty swallowing. Of these, tremor was significantly more common in the risperidone group (P=0.06). One child in each group had a value for serum glutamic-oxaloacetic transaminase that was more than twice the upper limit of the normal range at eight weeks, and one child in the placebo group had an elevated serum glutamic-pyruvic transaminase level. One child in the placebo group had a nonspecific, clinically insignificant change in cardiac conduction. The pulse, blood pressure, and results of routine laboratory tests did not differ significantly between the two groups. Eighteen children (8 in the risperidone group and 10 in the placebo group) had fever in association with a documented, time-limited illness.
Withdrawal from the Study
Three children in the risperidone group were withdrawn from the study because the treatment was not effective. One child in the placebo group was withdrawn because of a severe headache and a seizure attributed to the failure of a ventriculoatrial shunt. An additional 17 children in the placebo group did not complete the study for the following reasons: withdrawal of consent (1 child), nonadherence (1), loss to follow-up (3), and lack of efficacy (12). The rate of withdrawal was 35 percent (18 of 52 children) in the placebo group, as compared with 6 percent (3 of 49) in the risperidone group (P=0.001).
Discussion
In this trial, risperidone was safe and effective for the short-term treatment of tantrums, aggression, and self-injurious behavior in children with autistic disorder. Improvements were also observed in stereotypic behavior and hyperactivity. Scores on the Social Withdrawal subscale, which rates social isolation and interest in communicating with others, did not differ significantly between the risperidone and placebo groups. Adverse effects such as weight gain, increased appetite, fatigue, drowsiness, dizziness, drooling, tremor, and constipation were more common in the risperidone group. Most of these adverse effects were mild and resolved within a few weeks. Thus, the risk–benefit ratio for risperidone therapy appears to be favorable.
Our findings confirm the results of small, open-label trials of risperidone in children with autism or another pervasive developmental disorder.4 The benefits of risperidone in our study exceeded the improvements observed in a recent controlled study involving 38 adolescents with mental retardation and explosive behavior.25 In our study, there was a difference of 43 percentage points between the risperidone and placebo groups in the change from the base-line score on the Irritability subscale, whereas studies of haloperidol for the treatment of autism showed a difference of 15 to 20 percent between the placebo and active-treatment groups, depending on the measure.5 Our findings with respect to the rate and severity of adverse effects also differ from previous findings. Excessive sedation was reported in 78 percent of children who received haloperidol,6 as compared with generally mild sedation in 59 percent of the children in our study who received risperidone. An acute dystonic reaction occurred in 25 percent of haloperidol-treated patients6 but in none of the children in our trial who received risperidone. Although parents or primary caretakers reported tremor in a few of the children treated with risperidone, weekly neurologic assessments showed no abnormalities. The low risk of extrapyramidal symptoms in our study is consistent with the results of studies in adults.8 Nonetheless, the adverse events observed in our study and the lack of a clear benefit with regard to core symptoms of autism indicate that risperidone should be reserved for treatment of moderate-to-severe behavioral problems associated with autism.
There are several limitations to this study. First, the observation period was only eight weeks long. However, a majority of the children who were classified as having a positive response during the double-blind phase of the study (23 of 34) continued to show benefit at six months. Second, the study included only children with autistic disorder. It is not clear whether our findings can be generalized to children with other forms of pervasive developmental disorder. Third, although the mean doses of risperidone used in this study were not high, the study could not identify the minimal effective dose. Finally, we focused on specific behavioral problems rather than on the core symptoms of autism. Indeed, when designing the study, we were unable to identify a validated measure for the core symptoms of autism that was suitable for repeated administration. Our focus on severe behavioral problems leaves unanswered the question of whether pharmacologic therapy and behavioral treatment could have additive effects.
Supported by contracts from the National Institute of Mental Health (N01MH70009, to Dr. Scahill; N01MH70010, to Dr. McCracken; N01MH70001, to Dr. McDougle; and N01MH80011, to Dr. Aman), General Clinical Research Center grants from the National Institutes of Health (M01 RR00750, to Indiana University; M01 RR00052, to Johns Hopkins University; M01 RR00034, to Ohio State University; and M01 RR06022, to Yale University), and a grant from the Korczak Foundation (to Dr. Scahill). Study medications were donated by Janssen Pharmaceutica.
The content of this report does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. government.
We are indebted to Drs. C.T. Gordon (University of Maryland), Joseph DeVeaugh-Geiss (Duke University), Henrietta Leonard (Brown University), Richard Shader (Tufts University), and Susan Swedo (National Institute of Mental Health) of the Research Units on Pediatric Psychopharmacology Scientific Advisory Board, and to Dr. Phillip Walson (Children's Hospital Medical Center, Cincinnati), as well as to Erin Kustan and Caifeng Fu for assistance in preparing this report.
Source Information
Dr. Scahill accepts responsibility for the overall content and integrity of the manuscript. The authors of this report are James T. McCracken, M.D., James McGough, M.D., Bhavik Shah, M.D., Pegeen Cronin, Ph.D., and Daniel Hong, M.A., University of California, Los Angeles; Michael G. Aman, Ph.D., L. Eugene Arnold, M.D., Ronald Lindsay, M.D., Patricia Nash, M.D., and Jill Hollway, B.A., Ohio State University, Columbus; Christopher J. McDougle, M.D., David Posey, M.D., Naomi Swiezy, Ph.D., and Arlene Kohn, B.A., Indiana University, Indianapolis; Lawrence Scahill, M.S.N., Ph.D., Andres Martin, M.D., Kathleen Koenig, M.S.N., Fred Volkmar, M.D., Deirdre Carroll, M.S.N., and Allison Lancor, B.S., Yale University, New Haven, Conn.; Elaine Tierney, M.D., Jaswinder Ghuman, M.D., Nilda M. Gonzalez, M.D., and Marco Grados, M.D., Kennedy Krieger Institute, Baltimore; Benedetto Vitiello, M.D., and Louise Ritz, M.B.A., National Institute of Mental Health, Bethesda, Md.; Mark Davies, M.P.H., Columbia University, New York; and James Robinson, M.E.D., and Don McMahon, M.S., Nathan Kline Institute, Orangeburg, N.Y.
Address reprint requests to Dr. Lawrence Scahill at the Yale Child Study Center, P.O. Box 207900, New Haven, CT 06520, or at lawrence.scahill@yale.edu.
- References
References
1
Chakrabarti S ,Fombonne E . Pervasive developmental disorders in preschool children. JAMA 2001;285:3093-3099
CrossRef | Web of Science | Medline2
Fombonne E ,du Mazaubrun C . Prevalence of infantile autism in four French regions. Soc Psychiatry Psychiatr Epidemiol 1992;27:203-210
CrossRef | Web of Science | Medline3
Schreibman L . Intensive behavioral/psychoeducational treatments for autism: research needs and future directions. J Autism Dev Disord 2000;30:373-378
CrossRef | Web of Science | Medline4
McDougle CJ ,Scahill L ,McCracken JT , et al. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network: background and rationale for an initial controlled study of risperidone. Child Adolesc Psychiatr Clin N Am 2000;9:201-224
Web of Science | Medline5
Anderson LT ,Campbell M ,Adams P ,Small AM ,Perry R ,Shell J . The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord 1989;19:227-239
CrossRef | Web of Science | Medline6
Anderson LT ,Campbell M ,Grega DM ,Perry R ,Small AM ,Green WH . Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry 1984;141:1195-1202
Web of Science | Medline7
Campbell M ,Armenteros JL ,Malone RP ,Adams PB ,Eisenberg ZW ,Overall JE . Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J Am Acad Child Adolesc Psychiatry 1997;36:835-843
CrossRef | Web of Science | Medline8
Glick ID ,Murray SR ,Vasudevan P ,Marder SR ,Hu RJ . Treatment with atypical antipsychotics: new indications and new populations. J Psychiatr Res 2001;35:187-191
CrossRef | Web of Science | Medline9
Kapur S ,Seeman P . Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001;158:360-369
CrossRef | Web of Science | Medline10
Aman MG ,Madrid A . Atypical antipsychotics in persons with developmental disabilities. Ment Retard Dev Disabil Res Rev 1999;5:253-263
CrossRef | Web of Science11
McDougle CJ ,Holmes JP ,Carlson DC ,Pelton GH ,Cohen DJ ,Price LH . A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry 1998;55:633-641
CrossRef | Web of Science | Medline12
McDougle CJ ,Holmes JP ,Bronson MR , et al. Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Am Acad Child Adolesc Psychiatry 1997;36:685-693
CrossRef | Web of Science | Medline13
Fisman S ,Steele M . Use of risperidone in pervasive developmental disorders: a case series. J Child Adolesc Psychopharmacol 1996;6:177-190
CrossRef | Web of Science | Medline14
Scahill L ,McCracken J ,McDougle CJ , et al. Methodological issues in designing a multisite trial of risperidone in children and adolescents with autism. J Child Adolesc Psychopharmacol 2001;11:377-388
CrossRef | Web of Science | Medline15
Diagnostic and statistical manual of mental disorders, 4th ed.: DSM-IV. Washington, D.C.: American Psychiatric Association, 1994.
16
Lord C ,Pickles A ,McLennan J , et al. Diagnosing autism: analyses of data from the Autism Diagnostic Interview. J Autism Dev Disord 1997;27:501-517
CrossRef | Web of Science | Medline17
Carter AS ,Volkmar FR ,Sparrow SS , et al. The Vineland Adaptive Behavior Scales: supplementary norms for individuals with autism. J Autism Dev Disord 1998;28:287-302
CrossRef | Web of Science | Medline18
Guy W. ECDEU assessment manual for psychopharmacology. Rev. Rockville, Md.: National Institute of Mental Health, 1976. (DHEW publication no. (ADM) 76-338.)
19
Marshburn EC ,Aman MG . Factor validity and norms for the aberrant behavior checklist in a community sample of children with mental retardation. J Autism Dev Disord 1992;22:357-373
CrossRef | Web of Science | Medline20
Brown EC ,Aman MG ,Havercamp SM . Factor analysis and norms for parent ratings on the Aberrant Behavior Checklist -- Community for young people in special education. Res Dev Disabil 2002;23:45-60
CrossRef | Web of Science | Medline21
Arnold LE ,Aman MG ,Martin A , et al. Assessment in multisite randomized clinical trials of patients with autistic disorder: the Autism RUPP Network. J Autism Dev Disord 2000;30:99-111
CrossRef | Web of Science | Medline22
Simpson GM ,Angus JW . A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11-19
CrossRef | Medline23
Gibbons RD ,Hedeker D ,Elkin I , et al. Some conceptual and statistical issues in analysis of longitudinal psychiatric data: application to the NIMH treatment of Depression Collaborative Research Program dataset. Arch Gen Psychiatry 1993;50:739-750
Web of Science | Medline24
Littell RC, Milliken GA, Stroup WW, Wolfinger RD. SAS system for mixed models. Cary, N.C.: SAS Institute, 1996.
25
Buitelaar JK ,van der Gaag RJ ,Cohen-Kettenis P ,Melman CT . A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry 2001;62:239-248
CrossRef | Web of Science | Medline
- Citing Articles (345)
Citing Articles
1
Amir Hossein Memari, Vahid Ziaee, Sara Beygi, Pouria Moshayedi, Fatemeh Sadat Mirfazeli. (2012) Overuse of psychotropic medications among children and adolescents with autism spectrum disorders: Perspective from a developing country. Research in Developmental Disabilities 33:2, 563-569
CrossRef2
Ryan T. Thorson, Johnny L. Matson. (2012) Cutoff scores for the Autism Spectrum Disorder – Comorbid for Children (ASD-CC). Research in Autism Spectrum Disorders 6:1, 556-559
CrossRef3
Susan Dickerson Mayes, Susan L. Calhoun, Richa Aggarwal, Courtney Baker, Santoshkumar Mathapati, Robert Anderson, Christopher Petersen. (2012) Explosive, oppositional, and aggressive behavior in children with autism compared to other clinical disorders and typical children. Research in Autism Spectrum Disorders 6:1, 1-10
CrossRef4
Stephen I Deutsch, Maria R Urbano, Christian Zemlin. (2012) Mouse models have limitations for development of medications for autism spectrum disorders, but also show much promise. Future Neurology 7:1, 1-4
CrossRef5
Jia Wang, Xue Zhou, Wei Xia, Cai-Hong Sun, Li-Jie Wu, Jian-Li Wang, Akemi Tomoda. (2012) Parent-reported health care expenditures associated with autism spectrum disorders in Heilongjiang Province, China. BMC Health Services Research 12:1, 7
CrossRef6
Thomas W. Frazier, Paul T. Shattuck, Sarah Carter Narendorf, Benjamin P. Cooper, Mary Wagner, Edward L. Spitznagel. (2011) Prevalence and Correlates of Psychotropic Medication Use in Adolescents with an Autism Spectrum Disorder with and without Caregiver-Reported Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology111213120153001
CrossRef7
Sharon Zmigrod, Leo M. J. Sonneville, Lorenza S. Colzato, Hanna Swaab, Bernhard Hommel. (2011) Cognitive control of feature bindings: evidence from children with autistic spectrum disorder. Psychological Research
CrossRef8
Evdokia Anagnostou, Robin Hansen. (2011) Medical treatment overview. Current Opinion in Pediatrics 23:6, 621-627
CrossRef9
Haruhiro Higashida, Shigeru Yokoyama, Mitsuru Kikuchi, Toshio Munesue. (2011) CD38 and its role in oxytocin secretion and social behavior. Hormones and Behavior
CrossRef10
Lawrence Scahill, Christopher J. McDougle, Michael G. Aman, Cynthia Johnson, Benjamin Handen, Karen Bearss, James Dziura, Eric Butter, Naomi G. Swiezy, L. Eugene Arnold, Kimberly A. Stigler, Denis D. Sukhodolsky, Luc Lecavalier, Stacie L. Pozdol, Roumen Nikolov, Jill A. Hollway, Patricia Korzekwa, Allison Gavaletz, Arlene E. Kohn, Kathleen Koenig, Stacie Grinnon, James A. Mulick, Sunkyung Yu, Benedetto Vitiello. (2011) Effects of Risperidone and Parent Training on Adaptive Functioning in Children With Pervasive Developmental Disorders and Serious Behavioral Problems. Journal of the American Academy of Child & Adolescent Psychiatry
CrossRef11
D. Périsse, V. Guinchat, J.A. Hellings, A. Baghdadli. (2011) Traitement pharmacologique des comportements problématiques associés aux troubles du spectre autistique : revue de la littérature. Neuropsychiatrie de l'Enfance et de l'Adolescence
CrossRef12
Matthew Siegel, Amy A. Beaulieu. (2011) Psychotropic Medications in Children with Autism Spectrum Disorders: A Systematic Review and Synthesis for Evidence-Based Practice. Journal of Autism and Developmental Disorders
CrossRef13
Zuzana Tobiasova, Klaas H. B. van der Lingen, Lawrence Scahill, James F. Leckman, Yan Zhang, Wookjin Chae, James T. McCracken, Christopher J. McDougle, Benedetto Vitiello, Elaine Tierney, Michael G. Aman, L. Eugene Arnold, Liliya Katsovich, Pieter J. Hoekstra, Fred Volkmar, Alfred L. M. Bothwell, Ivana Kawikova. (2011) Risperidone-Related Improvement of Irritability in Children with Autism Is not Associated with Changes in Serum of Epidermal Growth Factor and Interleukin-13. Journal of Child and Adolescent Psychopharmacology111109064355004
CrossRef14
A. M. Muehlmann, S. D. Kies, C. A. Turner, S. Wolfman, M. H. Lewis, D. P. Devine. (2011) Self-injurious behaviour: limbic dysregulation and stress effects in an animal model. Journal of Intellectual Disability Researchno-no
CrossRef15
Kaizad R. Munshi, Joseph Gonzalez-Heydrich, Tara Augenstein, Eugene J. D’Angelo. (2011) Evidence-Based Treatment Approach to Autism Spectrum Disorders. Pediatric Annals 40:11, 569-574
CrossRef16
Gemma L. Unwin, Shoumitro Deb. (2011) Efficacy of atypical antipsychotic medication in the management of behaviour problems in children with intellectual disabilities and borderline intelligence: A systematic review. Research in Developmental Disabilities 32:6, 2121-2133
CrossRef17
M. de Hert, M. Dobbelaere, E.M. Sheridan, D. Cohen, C.U. Correll. (2011) Efectos adversos metabólicos y endocrinos de los antipsicóticos de segunda generación en niños y adolescentes: una revisión sistemática de ensayos aleatorizados, controlados con placebo y guías de práctica clínica. Psiquiatría Biológica
CrossRef18
Lucy E. Rosenblatt, Sasikanth Gorantla, Jodi A. Torres, Rubin S. Yarmush, Surita Rao, Elyse R. Park, John W. Denninger, Herbert Benson, Gregory L. Fricchione, Bruce Bernstein, John B. Levine. (2011) Relaxation Response–Based Yoga Improves Functioning in Young Children with Autism: A Pilot Study. The Journal of Alternative and Complementary Medicine111012114620000
CrossRef19
Stephanie M. Sansone, Keith F. Widaman, Scott S. Hall, Allan L. Reiss, Amy Lightbody, Walter E. Kaufmann, Elizabeth Berry-Kravis, Ave Lachiewicz, Elaine C. Brown, David Hessl. (2011) Psychometric Study of the Aberrant Behavior Checklist in Fragile X Syndrome and Implications for Targeted Treatment. Journal of Autism and Developmental Disorders
CrossRef20
Janet L. Kowalski, Logan K. Wink, Kelly Blankenship, Cheryl D. Habenicht, Craig A. Erickson, Kimberly A. Stigler, Christopher J. McDougle. (2011) Paliperidone Palmitate in a Child with Autistic Disorder. Journal of Child and Adolescent Psychopharmacology 21:5, 491-493
CrossRef21
Howard Demb, Maria Valicenti-McDermott, Abegail Navarro, Keith Thomas Ayoob. (2011) The Effect of Long-Term Use of Risperidone on Body Weight of Children With an Autism Spectrum Disorder. Journal of Clinical Psychopharmacology 31:5, 669-670
CrossRef22
Jeremy Veenstra-VanderWeele, Randy D Blakely. (2011) Networking in Autism: Leveraging Genetic, Biomarker and Model System Findings in the Search for New Treatments. Neuropsychopharmacology
CrossRef23
Benjamin L. Handen, Johanna Taylor, Rameshwari Tumuluru. (2011) Psychopharmacological treatment of ADHD symptoms in children with autism spectrum disorder. International Journal of Adolescent Medicine and Health 23:3, 167-173
CrossRef24
O. Bonnot, L. Holzer. (2011) Utilisation des antipsychotiques chez l’enfant et l’adolescent. Neuropsychiatrie de l'Enfance et de l'Adolescence
CrossRef25
Cristan Farmer, Luc Lecavalier, Sunkyung Yu, L. Eugene Arnold, Christopher J. McDougle, Lawrence Scahill, Benjamin Handen, Cynthia R. Johnson, Kimberly A. Stigler, Karen Bearss, Naomi B. Swiezy, Michael G. Aman. (2011) Predictors and Moderators of Parent Training Efficacy in a Sample of Children with Autism Spectrum Disorders and Serious Behavioral Problems. Journal of Autism and Developmental Disorders
CrossRef26
Logan K. Wink, Craig A. Erickson, Kimberly A. Stigler, Christopher J. McDougle. (2011) Riluzole in Autistic Disorder. Journal of Child and Adolescent Psychopharmacology 21:4, 375-379
CrossRef27
Alessandro Zuddas, Roberta Zanni, Tatiana Usala. (2011) Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: A review of the randomized controlled studies. European Neuropsychopharmacology 21:8, 600-620
CrossRef28
Tamara Pringsheim, Darren Lam, Heidi Ching, Scott Patten. (2011) Metabolic and Neurological Complications of Second-Generation Antipsychotic Use in Children. Drug Safety 34:8, 651-668
CrossRef29
Craig A. Erickson, Kimberly A. Stigler, Logan K. Wink, Jennifer E. Mullett, Arlene Kohn, David J. Posey, Christopher J. McDougle. (2011) A prospective open-label study of aripiprazole in fragile X syndrome. Psychopharmacology 216:1, 85-90
CrossRef30
Katrina Williams, Danielle M Wheeler, Natalie Silove, Philip Hazell. (2011) Cochrane Review: Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Evidence-Based Child Health: A Cochrane Review Journal 6:4, 1044-1078
CrossRef31
A. Scheifes, J. J. Stolker, A. C. G. Egberts, H. L. I. Nijman, E. R. Heerdink. (2011) Representation of people with intellectual disabilities in randomised controlled trials on antipsychotic treatment for behavioural problems. Journal of Intellectual Disability Research 55:7, 650-664
CrossRef32
Heidi M. Sleister, Maria Gabriela Valdovinos. (2011) Why Research On the Pharmacogenetics of Atypical Antipsychotic-Induced Weight Gain in Individuals With Intellectual Disabilities Is Warranted. Journal of Mental Health Research in Intellectual Disabilities 4:2, 65-78
CrossRef33
Lawrence Scahill, James T. McCracken, Karen Bearss, Fay Robinson, Eric Hollander, Bryan King, Joel Bregman, Lin Sikich, Kimberly Dukes, Lisa Sullivan, Evdokia Anagnostou, Craig Donnelly, Young-Shin Kim, Louise Ritz, Deborah Hirtz, Ann Wagner. (2011) Design and Subject Characteristics in the Federally-Funded Citalopram Trial in Children with Pervasive Developmental Disorders. Journal of Autism and Developmental Disorders
CrossRef34
L Lit, F R Sharp, K Bertoglio, B Stamova, B P Ander, A D Sossong, R L Hendren. (2011) Gene expression in blood is associated with risperidone response in children with autism spectrum disorders. The Pharmacogenomics Journal
CrossRef35
Laurène Beherec, Simon Lambrey, Gwendoline Quilici, Antoine Rosier, Bruno Falissard, Olivier Guillin. (2011) Retrospective Review of Clozapine in the Treatment of Patients With Autism Spectrum Disorder and Severe Disruptive Behaviors. Journal of Clinical Psychopharmacology 31:3, 341-344
CrossRef36
Fernanda Valle Krieger, Gabriel Ferreira Pheula, Roberta Coelho, Thamis Zeni, Silzá Tramontina, Cristian Patrick Zeni, Luis Augusto Rohde. (2011) An Open-Label Trial of Risperidone in Children and Adolescents with Severe Mood Dysregulation. Journal of Child and Adolescent Psychopharmacology 21:3, 237-243
CrossRef37
Gagan Joshi, Joseph Biederman, Janet Wozniak, Robert Doyle, Paul Hammerness, Maribel Galdo, Nora Sullivan, Courtney Williams, Kristin Brethel, K. Yvonne Woodworth, Eric Mick. (2011) Response to Second Generation Antipsychotics in Youth with Comorbid Bipolar Disorder and Autism Spectrum Disorder. CNS Neuroscience & Therapeuticsno-no
CrossRef38
Stephen Bent, Kiah Bertoglio, Paul Ashwood, Alan Bostrom, Robert L. Hendren. (2011) A Pilot Randomized Controlled Trial of Omega-3 Fatty Acids for Autism Spectrum Disorder. Journal of Autism and Developmental Disorders 41:5, 545-554
CrossRef39
M. De Hert, M. Dobbelaere, E.M. Sheridan, D. Cohen, C.U. Correll. (2011) Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. European Psychiatry 26:3, 144-158
CrossRef40
Tami D. Benton. (2011) Aripiprazole to Treat Irritability Associated With Autism: A Placebo-Controlled, Fixed-Dose Trial. Current Psychiatry Reports 13:2, 77-79
CrossRef41
Akanksha Sharma, Steven R. Shaw. (2011) Efficacy of Risperidone in Managing Maladaptive Behaviors for Children With Autistic Spectrum Disorder: A Meta Analysis. Journal of Pediatric Health Care
CrossRef42
Cristan Ann Farmer, Michael G Aman. (2011) Aripiprazole for the treatment of irritability associated with autism. Expert Opinion on Pharmacotherapy 12:4, 635-640
CrossRef43
Robert J. Constantine, Rajiv Tandon, Marie McPherson, Ross Andel. (2011) Early Diagnoses and Psychotherapeutic Medication Treatment Experiences of a Cohort of Children Under 6 Years Old Who Received Antipsychotic Treatment in Florida's Medicaid Program. Journal of Child and Adolescent Psychopharmacology 21:1, 79-84
CrossRef44
H. C. Dow, A. S. Kreibich, K. A. Kaercher, G. M. V. Sankoorikal, E. D. Pauley, F. W. Lohoff, T. N. Ferraro, H. Li, E. S. Brodkin. (2011) Genetic dissection of intermale aggressive behavior in BALB/cJ and A/J mice. Genes, Brain and Behavior 10:1, 57-68
CrossRef45
Lucy E. Rosenblatt, Sasikanth Gorantla, Jodi A. Torres, Rubin S. Yarmush, Surita Rao, Elyse R. Park, John W. Denninger, Herbert Benson, Gregory L. Fricchione, Bruce Bernstein, John B. Levine. (2011) Relaxation Response–Based Yoga Improves Functioning in Young Children with Autism: A Pilot Study. The Journal of Alternative and Complementary Medicine111012114620000
CrossRef46
Efrain C. Azmitia, Jorawer S. Singh, Patricia M. Whitaker-Azmitia. (2011) Increased serotonin axons (immunoreactive to 5-HT transporter) in postmortem brains from young autism donors. Neuropharmacology 60:7-8, 1347
CrossRef47
Johnny L. Matson, Julie A. Hess. (2011) Psychotropic drug efficacy and side effects for persons with autism spectrum disorders. Research in Autism Spectrum Disorders 5:1, 230-236
CrossRef48
Eyup S Ercan, Burge Basay, Omer Basay, Sibel Durak, Burcu Ozbaran. (2011) Risperidone in the treatment of conduct disorder in preschool children without intellectual disability. Child and Adolescent Psychiatry and Mental Health 5:1, 10
CrossRef49
Stanley Fahn, Joseph Jankovic, Mark Hallett. 2011. Stereotypies. , 380-388.
CrossRef50
Susan Dickerson Mayes, Susan L. Calhoun, Michael J. Murray, Meesha Ahuja, Laura A. Smith. (2011) Anxiety, depression, and irritability in children with autism relative to other neuropsychiatric disorders and typical development. Research in Autism Spectrum Disorders 5:1, 474-485
CrossRef51
Lynne C. Huffman, Trenna L. Sutcliffe, Ima S. D. Tanner, Heidi M. Feldman. (2011) Management of Symptoms in Children With Autism Spectrum Disorders: A Comprehensive Review of Pharmacologic and Complementary-Alternative Medicine Treatments. Journal of Developmental & Behavioral Pediatrics 32:1, 56-68
CrossRef52
Robin Steinberg-Epstein, Teri Book, Sharon B. Wigal. (2011) Controversies Surrounding Pediatric Psychopharmacology. Advances in Pediatrics 58:1, 153-179
CrossRef53
Stanley Fahn, Joseph Jankovic, Mark Hallett. 2011. Tics and Tourette syndrome. , 350-379.
CrossRef54
Roberto Canitano, Valeria Scandurra. (2011) Psychopharmacology in autism: An update. Progress in Neuro-Psychopharmacology and Biological Psychiatry 35:1, 18-28
CrossRef55
Edwin D. Williamson, Andres Martin. (2010) Psychotropic Medications in Autism: Practical Considerations for Parents. Journal of Autism and Developmental Disorders
CrossRef56
Pieter J. Hoekstra, Pieter W. Troost, Bertine E. Lahuis, Hans Mulder, Erik J. Mulder, Barbara Franke, Jan K. Buitelaar, George M. Anderson, Lawrence Scahill, Ruud B. Minderaa. (2010) Risperidone-Induced Weight Gain in Referred Children with Autism Spectrum Disorders Is Associated with a Common Polymorphism in the 5-Hydroxytryptamine 2C Receptor Gene. Journal of Child and Adolescent Psychopharmacology 20:6, 473-477
CrossRef57
Logan K. Wink, Craig A. Erickson, Christopher J. McDougle. (2010) Pharmacologic Treatment of Behavioral Symptoms Associated With Autism and Other Pervasive Developmental Disorders. Current Treatment Options in Neurology 12:6, 529-538
CrossRef58
Karisa Cristina Rodrigues Belotto, Nádia Rezende Barbosa Raposo, Aline Siqueira Ferreira, Wagner Farid Gattaz. (2010) Relative bioavailability of two oral formulations of risperidone 2 mg: A single-dose, randomized-sequence, open-label, two-period crossover comparison in healthy Brazilian volunteers. Clinical Therapeutics 32:12, 2106-2115
CrossRef59
Gagan Joshi, Carter Petty, Janet Wozniak, Aude Henin, Ronna Fried, Maribel Galdo, Meghan Kotarski, Sarah Walls, Joseph Biederman. (2010) The Heavy Burden of Psychiatric Comorbidity in Youth with Autism Spectrum Disorders: A Large Comparative Study of a Psychiatrically Referred Population. Journal of Autism and Developmental Disorders 40:11, 1361-1370
CrossRef60
Judith S. Nijmeijer, Catharina A. Hartman, Nanda N.J. Rommelse, Marieke E. Altink, Cathelijne J.M. Buschgens, Ellen A. Fliers, Barbara Franke, Ruud B. Minderaa, Johan Ormel, Joseph A. Sergeant, Frank C. Verhulst, Jan K. Buitelaar, Pieter J. Hoekstra. (2010) Perinatal risk factors interacting with catechol O-methyltransferase and the serotonin transporter gene predict ASD symptoms in children with ADHD. Journal of Child Psychology and Psychiatry 51:11, 1242-1250
CrossRef61
Michael J. Murray. (2010) Attention-deficit/Hyperactivity Disorder in the Context of Autism Spectrum Disorders. Current Psychiatry Reports 12:5, 382-388
CrossRef62
Ayten Erdogan, Mehmet Goksin Karaman, Esra Ozdemir, Nihal Yurteri, Ali Evren Tufan, Mehmet Ali Kurcer. (2010) Six Months of Treatment with Risperidone May Be Associated with Nonsignificant Abnormalities of Liver Function Tests in Children and Adolescents: A Longitudinal, Observational Study from Turkey. Journal of Child and Adolescent Psychopharmacology 20:5, 407-413
CrossRef63
Gabrielle A. Carlson, Elizabeth B. Weller. 2010. Phenomenology and Treatment of Bipolar I Disorder in Children: A Critical Review. , 477-487.
CrossRef64
C T Correia, J P Almeida, P E Santos, A F Sequeira, C E Marques, T S Miguel, R L Abreu, G G Oliveira, A M Vicente. (2010) Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions. The Pharmacogenomics Journal 10:5, 418-430
CrossRef65
Ann P. Kaiser, Laura Lee McIntyre. (2010) Editorial: Introduction to Special Section on Evidence-Based Practices for Persons With Intellectual and Developmental Disabilities. American Journal on Intellectual and Developmental Disabilities 115:5, 357-363
CrossRef66
Katrina Williams, Danielle M Wheeler, Natalie Silove, Philip Hazell, Katrina Williams. 2010. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). .
CrossRef67
Stephen Bent, Robert L. Hendren. (2010) Improving the prediction of response to therapy in autism. Neurotherapeutics 7:3, 232-240
CrossRef68
Craig A. Erickson, Kimberly A. Stigler, David J. Posey, Christopher J. McDougle. (2010) Aripiprazole in autism spectrum disorders and fragile X syndrome. Neurotherapeutics 7:3, 258-263
CrossRef69
Lulu W. Wang, Elizabeth Berry-Kravis, Randi J. Hagerman. (2010) Fragile X: Leading the way for targeted treatments in autism. Neurotherapeutics 7:3, 264-274
CrossRef70
J.-L. Goeb, S. Marco, A. Duhamel, G. Kechid, R. Bordet, P. Thomas, P. Delion, R. Jardri. (2010) Effets secondaires métaboliques de la rispéridone dans les schizophrénies à début précoce. L'Encéphale 36:3, 242-252
CrossRef71
Nicte I Mejia, Joseph Jankovic. (2010) Tardive dyskinesia and withdrawal emergent syndrome in children. Expert Review of Neurotherapeutics 10:6, 893-901
CrossRef72
Virginia Chun-Nei Wong, Jie-Guang Sun. (2010) Randomized Controlled Trial of Acupuncture Versus Sham Acupuncture in Autism Spectrum Disorder. The Journal of Alternative and Complementary Medicine 16:5, 545-553
CrossRef73
Min Sung, Daniel S. S. Fung, Yiming Cai, Yoon Phaik Ooi. (2010) Pharmacological management in children and adolescents with pervasive developmental disorder. Australian and New Zealand Journal of Psychiatry 44:5, 410-428
CrossRef74
Jeremy Veenstra-VanderWeele. (2010) Increase in Valproic Acid Levels During Riluzole Treatment in an Adolescent with Autism. Journal of Child and Adolescent Psychopharmacology 20:2, 163-165
CrossRef75
Michael G. Aman, Eugene L. Arnold, Luc Lecavalier, Jill A. Hollway, James A. Mulick, Christopher J. McDougle, Naomi B. Swiezy, Kimberly A. Stigler, Benjamin L. Handen, Cynthia Johnson, Benedetto Vitiello, Karen Bearss, James Dziura, Lawrence Scahill. (2010) Dr. Aman et al. reply. Journal of the American Academy of Child & Adolescent Psychiatry 49:4, 407-408
CrossRef76
J. Otasowie, R. Duffy, J. Freeman, C. Hollis. (2010) Antipsychotic prescribing practice among child psychiatrists and community paediatricians. The Psychiatrist 34:4, 126-129
CrossRef77
Kelly Blankenship, Craig A. Erickson, Christopher J. McDougle. (2010) Pharmacotherapy of Autism and Related Disorders. Psychiatric Annals 40:4, 203-209
CrossRef78
Adelaide S. Robb. (2010) Pharmacotherapy for Aggression in Children and Adolescents. Psychiatric Annals 40:4, 231-236
CrossRef79
L. Eugene Arnold, Cristan Farmer, Helena Chmura Kraemer, Mark Davies, Andrea Witwer, Shirley Chuang, Robert DiSilvestro, Christopher J. McDougle, James McCracken, Benedetto Vitiello, Michael G. Aman, Lawrence Scahill, David J. Posey, Naomi B. Swiezy. (2010) Moderators, Mediators, and Other Predictors of Risperidone Response in Children with Autistic Disorder and Irritability. Journal of Child and Adolescent Psychopharmacology 20:2, 83-93
CrossRef80
Lewis Mehl-Madrona, Brenda Leung, Carla Kennedy, Sarah Paul, Bonnie J. Kaplan. (2010) Micronutrients Versus Standard Medication Management in Autism: A Naturalistic Case–Control Study. Journal of Child and Adolescent Psychopharmacology 20:2, 95-103
CrossRef81
Jill L Silverman, Seda S Tolu, Charlotte L Barkan, Jacqueline N Crawley. (2010) Repetitive Self-Grooming Behavior in the BTBR Mouse Model of Autism is Blocked by the mGluR5 Antagonist MPEP. Neuropsychopharmacology 35:4, 976-989
CrossRef82
Gabrielle A Carlson, Michael Potegal, David Margulies, Joann Basile, Zinoviy Gutkovich. (2010) Liquid risperidone in the treatment of rages in psychiatrically hospitalized children with possible bipolar disorder. Bipolar Disorders 12:2, 205-212
CrossRef83
Eric Hollander, William Chaplin, Latha Soorya, Stacey Wasserman, Sherry Novotny, Jade Rusoff, Nicole Feirsen, Lauren Pepa, Evdokia Anagnostou. (2010) Divalproex Sodium vs Placebo for the Treatment of Irritability in Children and Adolescents with Autism Spectrum Disorders. Neuropsychopharmacology 35:4, 990-998
CrossRef84
Carmen Moreno, Jessica Merchán-Naranjo, Mar Álvarez, Inmaculada Baeza, Jose A Alda, Carmen Martínez-Cantarero, Mara Parellada, Bernardo Sánchez, Elena de la Serna, Marisa Giráldez, Celso Arango. (2010) Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses. Bipolar Disorders 12:2, 172-184
CrossRef85
Yong Kee Choi, Taylor Moran-Gates, Matthew P. Gardner, Frank I. Tarazi. (2010) Effects of repeated risperidone exposure on serotonin receptor subtypes in developing rats. European Neuropsychopharmacology 20:3, 187-194
CrossRef86
Shunsuke Araki, Taro Ohji, Naoki Shiota, Kazushige Dobashi, Masayuki Shimono, Akira Shirahata. (2010) Successful risperidone treatment for behavioral disturbances in Prader-Willi syndrome. Pediatrics International 52:1, e1-e3
CrossRef87
Kimberly A. Stigler, Craig A. Erickson, Jennifer E. Mullett, David J. Posey, Christopher J. McDougle. (2010) Paliperidone for Irritability in Autistic Disorder. Journal of Child and Adolescent Psychopharmacology 20:1, 75-78
CrossRef88
Sema Kalkan Ucar, Burcu Ozbaran, Nagehan Demiral, Zeki Yuncu, Serpil Erermis, Mahmut Coker. (2010) Clinical overview of children with mucopolysaccharidosis type III A and effect of Risperidone treatment on children and their mothers psychological status. Brain and Development 32:2, 156-161
CrossRef89
Thomas W. Frazier, Eric A. Youngstrom, Travis Haycook, Aletta Sinoff, Francine Dimitriou, Julie Knapp, Leslie Sinclair. (2010) Effectiveness of Medication Combined with Intensive Behavioral Intervention for Reducing Aggression in Youth with Autism Spectrum Disorder. Journal of Child and Adolescent Psychopharmacology 20:3, 167
CrossRef90
Mark Olfson, Stephen Crystal, Cecilia Huang, Tobias Gerhard. (2010) Trends in Antipsychotic Drug Use by Very Young, Privately Insured Children. Journal of the American Academy of Child & Adolescent Psychiatry 49:1, 13-23
CrossRef91
J. A. Tsiouris. (2010) Pharmacotherapy for aggressive behaviours in persons with intellectual disabilities: treatment or mistreatment?. Journal of Intellectual Disability Research 54:1, 1-16
CrossRef92
Frank Häßler, Olaf Reis. (2010) Pharmacotherapy of disruptive behavior in mentally retarded subjects: A review of the current literature. Developmental Disabilities Research Reviews 16:3, 265-272
CrossRef93
P. Oliver-Africano, S. Dickens, Z. Ahmed, N. Bouras, S. Cooray, S. Deb, M. Knapp, M. Hare, M. Meade, B. Reece, S. Bhaumik, D. Harley, J. Piachaud, A. Regan, D. Ade Thomas, S. Karatela, B. Rao, T. Dzendrowskyj, L. Lenôtre, J. Watson, P. Tyrer. (2010) Overcoming the barriers experienced in conducting a medication trial in adults with aggressive challenging behaviour and intellectual disabilities. Journal of Intellectual Disability Research 54:1, 17-25
CrossRef94
Adelaide S. Robb. (2010) Managing irritability and aggression in autism spectrum disorders in children and adolescents. Developmental Disabilities Research Reviews 16:3, 258-264
CrossRef95
Helen Egger. (2010) A Perilous Disconnect. Journal of the American Academy of Child & Adolescent Psychiatry 49:1, 3-6
CrossRef96
Helen Egger. (2010) A Perilous Disconnect: Antipsychotic Drug Use in Very Young Children. Journal of the American Academy of Child & Adolescent Psychiatry 49:1, 3-6
CrossRef97
Magali Haas, Alan S. Unis, Jorge Armenteros, Margaret D. Copenhaver, Jorge A. Quiroz, Stuart F. Kushner. (2009) A 6-Week, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Risperidone in Adolescents with Schizophrenia. Journal of Child and Adolescent Psychopharmacology 19:6, 611-621
CrossRef98
Michael G. Aman, Christopher J. Mcdougle, Lawrence Scahill, Benjamin Handen, L. Eugene Arnold, Cynthia Johnson, Kimberly A. Stigler, Karen Bearss, Eric Butter, Naomi B. Swiezy, Denis D. Sukhodolsky, Yaser Ramadan, Stacie L. Pozdol, Roumen Nikolov, Luc Lecavalier, Arlene E. Kohn, Kathleen Koenig, Jill A. Hollway, Patricia Korzekwa, Allison Gavaletz, James A. Mulick, Kristy L. Hall, James Dziura, Louise Ritz, Stacie Trollinger, Sunkyung Yu, Benedetto Vitiello, Ann Wagner. (2009) Medication and Parent Training in Children With Pervasive Developmental Disorders and Serious Behavior Problems: Results From a Randomized Clinical Trial. Journal of the American Academy of Child & Adolescent Psychiatry 48:12, 1143-1154
CrossRef99
Patricia Oliver-Africano, Declan Murphy, Peter Tyrer. (2009) Aggressive Behaviour in Adults with Intellectual Disability. CNS Drugs 23:11, 903-913
CrossRef100
Magali Haas, Melissa P DelBello, Gahan Pandina, Stuart Kushner, Ilse Van Hove, Ilse Augustyns, Jorge Quiroz, Vivek Kusumakar. (2009) Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. Bipolar Disorders 11:7, 687-700
CrossRef101
Elizabeth Freeman Floyd, David E. McIntosh. (2009) Current practice in psychopharmacology for children and adolescents with autism spectrum disorders. Psychology in the Schools 46:9, 905-909
CrossRef102
Ronald N. Marcus, Randall Owen, Lisa Kamen, George Manos, Robert D. McQuade, William H. Carson, Michael G. Aman. (2009) A Placebo-Controlled, Fixed-Dose Study of Aripiprazole in Children and Adolescents With Irritability Associated With Autistic Disorder. Journal of the American Academy of Child & Adolescent Psychiatry 48:11, 1110-1119
CrossRef103
Maria G. Valdovinos, Samantha M. Nelson, Jennifer L. Kuhle, Abigail M. Dierks. (2009) Using Analogue Functional Analysis to Measure Variations in Problem Behavior Rate and Function After Psychotropic Medication Changes: A Clinical Demonstration. Journal of Mental Health Research in Intellectual Disabilities 2:4, 279-293
CrossRef104
Marc Weeden, Kristal Ehrhardt, Alan Poling. (2009) Conspicuous by the their absence: Studies comparing and combining risperidone and applied behavior analysis to reduce challenging behavior in children with autism. Research in Autism Spectrum Disorders 3:4, 905-912
CrossRef105
Robert W. Lovell. 2009. Psychopharmacology: Child and Adolescent. .
CrossRef106
Anna J. Esbensen, Jan S. Greenberg, Marsha Mailick Seltzer, Michael G. Aman. (2009) A Longitudinal Investigation of Psychotropic and Non-Psychotropic Medication Use Among Adolescents and Adults with Autism Spectrum Disorders. Journal of Autism and Developmental Disorders 39:9, 1339-1349
CrossRef107
Jeannette Y. Wick, Guido R. Zanni. (2009) Autism and Aging: Hardly Out of the Woods. The Consultant Pharmacist 24:9, 648-658
CrossRef108
(2009) Practice Parameter on the Use of Psychotropic Medication in Children and Adolescents. Journal of the American Academy of Child & Adolescent Psychiatry 48:9, 961-973
CrossRef109
Yvette Roke, Peter N. van Harten, Annemieke M. Boot, Jan K. Buitelaar. (2009) Antipsychotic Medication in Children and Adolescents: A Descriptive Review of the Effects on Prolactin Level and Associated Side Effects. Journal of Child and Adolescent Psychopharmacology 19:4, 403-414
CrossRef110
Tobias Gerhard, Benjamin Chavez, Mark Olfson, Stephen Crystal. (2009) National Patterns in the Outpatient Pharmacological Management of Children and Adolescents With Autism Spectrum Disorder. Journal of Clinical Psychopharmacology 29:3, 307-310
CrossRef111
Jeremy Veenstra-VanderWeele, Tammy N. Jessen, Brent J. Thompson, Michelle Carter, Harish C. Prasad, Jennifer A. Steiner, James. S. Sutcliffe, Randy D. Blakely. (2009) Modeling rare gene variation to gain insight into the oldest biomarker in autism: construction of the serotonin transporter Gly56Ala knock-in mouse. Journal of Neurodevelopmental Disorders 1:2, 158-171
CrossRef112
Kimberly A. Stigler, Jonathan T. Diener, Arlene E. Kohn, Lang Li, Craig A. Erickson, David J. Posey, Christopher J. McDougle. (2009) Aripiprazole in Pervasive Developmental Disorder Not Otherwise Specified and Asperger's Disorder: A 14-Week, Prospective, Open-Label Study. Journal of Child and Adolescent Psychopharmacology 19:3, 265-274
CrossRef113
Benjamin L. Handen, Raun D. Melmed, Robin L. Hansen, Michael G. Aman, David L. Burnham, Jon B. Bruss, Christopher J. McDougle. (2009) A Double-Blind, Placebo-Controlled Trial of Oral Human Immunoglobulin for Gastrointestinal Dysfunction in Children with Autistic Disorder. Journal of Autism and Developmental Disorders 39:5, 796-805
CrossRef114
Jared J. Schwartzer, Randall L. Morrison, Lesley A. Ricci, Richard H. Melloni. (2009) Paliperidone suppresses the development of the aggressive phenotype in a developmentally sensitive animal model of escalated aggression. Psychopharmacology 203:4, 653-663
CrossRef115
Lawrence Scahill, Michael G. Aman, Christopher J. McDougle, L. Eugene Arnold, James T. McCracken, Benjamin Handen, Cynthia Johnson, James Dziura, Eric Butter, Denis Sukhodolsky, Naomi Swiezy, James Mulick, Kimberly Stigler, Karen Bearss, Louise Ritz, Ann Wagner, Benedetto Vitiello. (2009) Trial Design Challenges When Combining Medication and Parent Training in Children with Pervasive Developmental Disorders. Journal of Autism and Developmental Disorders 39:5, 720-729
CrossRef116
Gabriele Masi, Angela Cosenza, Stefania Millepiedi, Filippo Muratori, Cinzia Pari, Francesco Salvadori. (2009) Aripiprazole Monotherapy in Children and Young Adolescents with Pervasive Developmental Disorders. CNS Drugs 23:6, 511-521
CrossRef117
Michael Potegal, Gabrielle A. Carlson, David Margulies, Joann Basile, Zinoviy A. Gutkovich, Melanie Wall. (2009) The behavioral organization, temporal characteristics, and diagnostic concomitants of rage outbursts in child psychiatric inpatients. Current Psychiatry Reports 11:2, 127-133
CrossRef118
Roumen N. Nikolov, Karen E. Bearss, Jelle Lettinga, Craig Erickson, Maria Rodowski, Michael G. Aman, James T. McCracken, Christopher J. McDougle, Elaine Tierney, Benedetto Vitiello, L. Eugene Arnold, Bhavik Shah, David J. Posey, Louise Ritz, Lawrence Scahill. (2009) Gastrointestinal Symptoms in a Sample of Children with Pervasive Developmental Disorders. Journal of Autism and Developmental Disorders 39:3, 405-413
CrossRef119
Laudan B. Jahromi, Connie L. Kasari, James T. McCracken, Lisa S-Y. Lee, Michael G. Aman, Christopher J. McDougle, Lawrence Scahill, Elaine Tierney, L. Eugene Arnold, Benedetto Vitiello, Louise Ritz, Andrea Witwer, Erin Kustan, Jaswinder Ghuman, David J. Posey. (2009) Positive Effects of Methylphenidate on Social Communication and Self-Regulation in Children with Pervasive Developmental Disorders and Hyperactivity. Journal of Autism and Developmental Disorders 39:3, 395-404
CrossRef120
Lis West, Julee Waldrop, Susan Brunssen. (2009) Pharmacologic Treatment for the Core Deficits and Associated Symptoms of Autism in Children. Journal of Pediatric Health Care 23:2, 75-89
CrossRef121
D. T. Page, O. J. Kuti, C. Prestia, M. Sur. (2009) Haploinsufficiency for Pten and Serotonin transporter cooperatively influences brain size and social behavior. Proceedings of the National Academy of Sciences 106:6, 1989-1994
CrossRef122
Yong Kee Choi, Matthew P. Gardner, Frank I. Tarazi. (2009) Effects of risperidone on glutamate receptor subtypes in developing rat brain. European Neuropsychopharmacology 19:2, 77-84
CrossRef123
Daniel P. Dickstein, Kenneth E. Towbin, Jan Willem Van Der Veen, Brendan A. Rich, Melissa A. Brotman, Lisa Knopf, Laura Onelio, Daniel S. Pine, Ellen Leibenluft. (2009) Randomized Double-Blind Placebo-Controlled Trial of Lithium in Youths with Severe Mood Dysregulation. Journal of Child and Adolescent Psychopharmacology 19:1, 61-73
CrossRef124
M. Haas, M. Eerdekens, S. Kushner, J. Singer, I. Augustyns, J. Quiroz, G. Pandina, V. Kusumakar. (2009) Efficacy, safety and tolerability of two risperidone dosing regimens in adolescent schizophrenia: double-blind study. The British Journal of Psychiatry 194:2, 158
CrossRef125
Laura Arnstein Carpenter, Latha Soorya, Danielle Halpern. (2009) Asperger’s Syndrome and High-Functioning Autism. Pediatric Annals 38:1, 30-35
CrossRef126
Richard E. D'Alli. 2009. CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY. , 885-910.
CrossRef127
Marc R. Woodbury-Smith, Fred R. Volkmar. (2009) Asperger syndrome. European Child & Adolescent Psychiatry 18:1, 2-11
CrossRef128
Richard P. Malone, Ayesha Waheed. (2009) The Role of Antipsychotics in the Management of Behavioural Symptoms in Children and Adolescents with Autism. Drugs 69:5, 535-548
CrossRef129
Fred Volkmar, Lisa Wiesner. 2009. AUTISM AND RELATED DISORDERS. , 675-685.
CrossRef130
Christopher J. Kratochvil, Benedetto Vitiello. (2008) Recent NIMH Clinical Trials and Implications for Practice. Journal of the American Academy of Child & Adolescent Psychiatry 47:12, 1369-1374
CrossRef131
Christian Fleischhaker, Philip Heiser, Klaus Hennighausen, Beate Herpertz-Dahlmann, Kristian Holtkamp, Claudia Mehler-Wex, Reinhold Rauh, Helmut Remschmidt, Eberhard Schulz, Andreas Warnke. (2008) Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine and risperidone. Journal of Neural Transmission 115:11, 1599-1608
CrossRef132
Zoran Brkanac, Wendy H Raskind, Bryan H King. (2008) Pharmacology and genetics of autism: implications for diagnosis and treatment. Personalized Medicine 5:6, 599-607
CrossRef133
David J. Posey, Craig A. Erickson, Christopher J. McDougle. (2008) Developing Drugs for Core Social and Communication Impairment in Autism. Child and Adolescent Psychiatric Clinics of North America 17:4, 787-801
CrossRef134
Elizabeth Berry-Kravis, Allison Sumis, Ok-Kyung Kim, Rebecca Lara, Joanne Wuu. (2008) Characterization of Potential Outcome Measures for Future Clinical Trials in Fragile X Syndrome. Journal of Autism and Developmental Disorders 38:9, 1751-1757
CrossRef135
Amit M. Deokar, Marlene B. Huff, Hatim A. Omar. (2008) Clinical Management of Adolescents with Autism. Pediatric Clinics of North America 55:5, 1147-1157
CrossRef136
Cathy Budman, Barbara J. Coffey, Rachel Shechter, Matthew Schrock, Natalie Wieland, Arie Spirgel, Elizabeth Simon. (2008) Aripiprazole in Children and Adolescents with Tourette Disorder with and without Explosive Outbursts. Journal of Child and Adolescent Psychopharmacology 18:5, 509-515
CrossRef137
Lawrence Scahill, Michael G. Aman, James T. McCracken, Christopher J. McDougle, Benedetto Vitiello. (2008) Beware of Over-Interpreting Negative Trials. Journal of Autism and Developmental Disorders 38:9, 1609-1610
CrossRef138
Jared J. Schwartzer, Daniel F. Connor, Randall L. Morrison, Lesley A. Ricci, Richard H. Melloni. (2008) Repeated risperidone administration during puberty prevents the generation of the aggressive phenotype in a developmentally immature animal model of escalated aggression. Physiology & Behavior 95:1-2, 176-181
CrossRef139
Donna L Londino, Diana Mattingly, David S Janowsky. 2008. Biological Treatment of Asperger'sDisorder. , 259-292.
CrossRef140
Ismo Makkonen, Raili Riikonen, Hannu Kokki, Mauno M Airaksinen, Jyrki T Kuikka. (2008) Serotonin and dopamine transporter binding in children with autism determined by SPECT. Developmental Medicine & Child Neurology 50:8, 593-597
CrossRef141
David S. Mandell. (2008) Psychiatric Hospitalization Among Children with Autism Spectrum Disorders. Journal of Autism and Developmental Disorders 38:6, 1059-1065
CrossRef142
Lawrence Scahill. (2008) How Do I Decide Whether or Not to Use Medication for My Child with Autism? Should I Try Behavior Therapy First?. Journal of Autism and Developmental Disorders 38:6, 1197-1198
CrossRef143
J. de Leon, N. B. Sandson, K. L. Cozza. (2008) A Preliminary Attempt to Personalize Risperidone Dosing Using Drug-Drug Interactions and Genetics: Part II. Psychosomatics 49:4, 347-361
CrossRef144
Michael G. Aman, Jill A. Hollway, Christopher J. McDougle, Lawrence Scahill, Elaine Tierney, James T. McCracken, L. Eugene Arnold, Benedetto Vitiello, Louise Ritz, Allison Gavaletz, Pegeen Cronin, Naomi Swiezy, Courtney Wheeler, Kathleen Koenig, Jaswinder K. Ghuman, David J. Posey. (2008) Cognitive Effects of Risperidone in Children with Autism and Irritable Behavior. Journal of Child and Adolescent Psychopharmacology 18:3, 227-236
CrossRef145
Johnny L. Matson, Timothy Dempsey. (2008) Autism Spectrum Disorders: Pharmacotherapy for Challenging Behaviors. Journal of Developmental and Physical Disabilities 20:2, 175-191
CrossRef146
Ayten Erdogan, Nuray Atasoy, Hanife Akkurt, Devrim Ozturk, Elif Karaahmet, Irem Yalug, Kivanc Yalug, Handan Ankarali, Ibrahim Balcioglu. (2008) Risperidone and liver function tests in children and adolescents: A short-term prospective study. Progress in Neuro-Psychopharmacology and Biological Psychiatry 32:3, 849-857
CrossRef147
Mihir S. Parikh, Alexander Kolevzon, Eric Hollander. (2008) Psychopharmacology of Aggression in Children and Adolescents with Autism: A Critical Review of Efficacy and Tolerability. Journal of Child and Adolescent Psychopharmacology 18:2, 157-178
CrossRef148
Daniel F. Connor, Thomas J. McLaughlin, Mary Jeffers-Terry. (2008) Randomized Controlled Pilot Study of Quetiapine in the Treatment of Adolescent Conduct Disorder. Journal of Child and Adolescent Psychopharmacology 18:2, 140-156
CrossRef149
Ana Soledade Graeff-Martins, Martine F. Flament, John Fayyad, Sam Tyano, Peter Jensen, Luis Augusto Rohde. (2008) Diffusion of efficacious interventions for children and adolescents with mental health problems. Journal of Child Psychology and Psychiatry 49:3, 335-352
CrossRef150
Ming-zhu Huang, Jian-zhong Shentu, Jun-chun Chen, Jian Liu, Hui-li Zhou. (2008) Determination of risperidone in human plasma by HPLC-MS/MS and its application to a pharmacokinetic study in Chinese volunteers. Journal of Zhejiang University SCIENCE B 9:2, 114-120
CrossRef151
Suha Miral, Ozlem Gencer, F. Neslihan Inal-Emiroglu, Burak Baykara, Aysen Baykara, Eray Dirik. (2008) Risperidone versus haloperidol in children and adolescents with AD. European Child & Adolescent Psychiatry 17:1, 1-8
CrossRef152
Michael F. Caldwell, Melanie Malterer, Deborah Umstead, David J. McCormick. (2008) A Retrospective Evaluation of Adjunctive Risperidone Treatment in Severely Behaviorally Disordered Boys Receiving Psychosocial Treatment. Journal of Child and Adolescent Psychopharmacology 18:1, 34-43
CrossRef153
Akane Nakasato, Yasushi Nakatani, Yoshinari Seki, Naohisa Tsujino, Masahiro Umino, Hideho Arita. (2008) Swim stress exaggerates the hyperactive mesocortical dopamine system in a rodent model of autism. Brain Research 1193, 128-135
CrossRef154
David J. Posey, Kimberly A. Stigler, Craig A. Erickson, Christopher J. McDougle. (2008) Antipsychotics in the treatment of autism. Journal of Clinical Investigation 118:1, 6-14
CrossRef155
Thaddeus P. Ulzen, Richard E. Powers. (2008) A Review of Empirical Evidence of Somatic Treatment Options for the MI/DD Population. Psychiatric Quarterly 79:3, 265
CrossRef156
Elizabeth Berry-Kravis, Allison Sumis, Crystal Hervey, Michael Nelson, Stephen W. Porges, Ning Weng, Ivan Jeanne Weiler, William T. Greenough. (2008) Open-Label Treatment Trial of Lithium to Target the Underlying Defect in Fragile X Syndrome. Journal of Developmental & Behavioral Pediatrics 29:4, 293
CrossRef157
Michael G. Aman, Cristan A. Farmer, Jill Hollway, L.Eugene Arnold. (2008) Treatment of Inattention, Overactivity, and Impulsiveness in Autism Spectrum Disorders. Child and Adolescent Psychiatric Clinics of North America 17:4, 713
CrossRef158
CHRISTOPH U. CORRELL, Christopher J. Kratochvil. (2008) Antipsychotic Use in Children and Adolescents: Minimizing Adverse Effects to Maximize Outcomes. Journal of the American Academy of Child & Adolescent Psychiatry 47:1, 9-20
CrossRef159
George T. Capone, Parag Goyal, Marco Grados, Brandon Smith, Heather Kammann. (2008) Risperidone Use in Children with Down Syndrome, Severe Intellectual Disability, and Comorbid Autistic Spectrum Disorders: A Naturalistic Study. Journal of Developmental & Behavioral Pediatrics 29:2, 106
CrossRef160
Sufen Chiu, Felicia Widjaja, Marsha E. Bates, Gerald T. Voelbel, Gahan Pandina, Joelle Marble, Jeremy A. Blank, Josh Day, Norman Brule, Robert L. Hendren. (2008) Anterior cingulate volume in pediatric bipolar disorder and autism. Journal of Affective Disorders 105:1-3, 93-99
CrossRef161
Kimberly A. Stigler, Christopher J. McDougle. (2008) Pharmacotherapy of Irritability in Pervasive Developmental Disorders. Child and Adolescent Psychiatric Clinics of North America 17:4, 739
CrossRef162
Lesley J Scott, Sohita Dhillon. (2008) Spotlight on Risperidone in Irritability Associated with Autistic??Disorder in Children and??Adolescents???. CNS Drugs 22:3, 259-262
CrossRef163
Denis G. Sukhodolsky, Lawrence Scahill, Kenneth D. Gadow, L. Eugene Arnold, Michael G. Aman, Christopher J. McDougle, James T. McCracken, Elaine Tierney, Susan Williams White, Luc Lecavalier, Benedetto Vitiello. (2008) Parent-Rated Anxiety Symptoms in Children with Pervasive Developmental Disorders: Frequency and Association with Core Autism Symptoms and Cognitive Functioning. Journal of Abnormal Child Psychology 36:1, 117-128
CrossRef164
Peter Tyrer, Patricia C Oliver-Africano, Zed Ahmed, Nick Bouras, Sherva Cooray, Shoumitro Deb, Declan Murphy, Monica Hare, Michael Meade, Ben Reece, Kofi Kramo, Sabyasachi Bhaumik, David Harley, Adrienne Regan, David Thomas, Bharti Rao, Bernard North, Joseph Eliahoo, Shamshad Karatela, Anju Soni, Mike Crawford. (2008) Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial. The Lancet 371:9606, 57-63
CrossRef165
Shawn F. Smyth, David Q. Beversdorf. (2007) Lack of Dopaminergic Modulation of Cognitive Flexibility. Cognitive and Behavioral Neurology 20:4, 225-229
CrossRef166
Richard P. Malone, Mary Anne Delaney, Susan B. Hyman, Jacqueline R. Cater. (2007) Ziprasidone in Adolescents with Autism: An Open-Label Pilot Study. Journal of Child and Adolescent Psychopharmacology 17:6, 779-790
CrossRef167
MARY MARGARET GLEASON, HELEN LINK EGGER, GRAHAM J. EMSLIE, LAURENCE L. GREENHILL, ROBERT A. KOWATCH, ALICIA F. LIEBERMAN, JOAN L. LUBY, JUDITH OWENS, LAWRENCE D. SCAHILL, MICHAEL S. SCHEERINGA, BRIAN STAFFORD, BRIAN WISE, CHARLES H. ZEANAH. (2007) Psychopharmacological Treatment for Very Young Children: Contexts and Guidelines. Journal of the American Academy of Child & Adolescent Psychiatry 46:12, 1532-1572
CrossRef168
J. Helen Yoo, Maria G. Valdovinos, Dean C. Williams. (2007) Relevance of Donepezil in Enhancing Learning and Memory in Special Populations: A Review of the Literature. Journal of Autism and Developmental Disorders 37:10, 1883-1901
CrossRef169
Jason Brinkley, Laura Nations, Ruth K. Abramson, Alicia Hall, Harry H. Wright, Robin Gabriels, John R. Gilbert, Margaret A. O. Pericak-Vance, Michael L. Cuccaro. (2007) Factor Analysis of the Aberrant Behavior Checklist in Individuals with Autism Spectrum Disorders. Journal of Autism and Developmental Disorders 37:10, 1949-1959
CrossRef170
Cynthia R. Ellis, Richard E. Lutz, G. Bradley Schaefer, Kathryn E. Woods. (2007) Physician collaboration involving students with Autism Spectrum Disorders. Psychology in the Schools 44:7, 737-747
CrossRef171
Shoumitro Deb, Gemma L Unwin. (2007) Psychotropic medication for behaviour problems in people with intellectual disability: a review of the current literature. Current Opinion in Psychiatry 20:5, 461-466
CrossRef172
Lesley A. Ricci, Daniel F. Connor, Randall Morrison, Richard H. Melloni. (2007) Risperidone Exerts Potent Anti-aggressive Effects in a Developmentally Immature Animal Model of Escalated Aggression. Biological Psychiatry 62:3, 218-225
CrossRef173
Arun V Ravindran, Cheryl Bradbury, Martha McKay, Tricia L da Silva. (2007) Novel uses for risperidone: focus on depressive, anxiety and behavioral disorders. Expert Opinion on Pharmacotherapy 8:11, 1693-1710
CrossRef174
Gahan J. Pandina, Robert Bilder, Philip D. Harvey, Richard S.E. Keefe, Michael G. Aman, Georges Gharabawi. (2007) Risperidone and Cognitive Function in Children With Disruptive Behavior Disorders. Biological Psychiatry 62:3, 226-234
CrossRef175
Scott M Myers. (2007) The status of pharmacotherapy for autism spectrum disorders. Expert Opinion on Pharmacotherapy 8:11, 1579-1603
CrossRef176
Lawrence Scahill, Kathleen Koenig, Deirdre H. Carroll, Maryellen Pachler. (2007) Psychopharmacology.. Journal of Child and Adolescent Psychiatric Nursing 20:3, 188-190
CrossRef177
Michael G. Aman, Alexander A. Vinks, Bart Remmerie, Erik Mannaert, Yaser Ramadan, Jessica Masty, Ronald L. Lindsay, Krista Malone. (2007) Plasma Pharmacokinetic Characteristics of Risperidone and Their Relationship to Saliva Concentrations in Children with Psychiatric or Neurodevelopmental Disorders. Clinical Therapeutics 29:7, 1476-1486
CrossRef178
Cynthia R. Johnson, Benjamin L. Handen, Eric Butter, Ann Wagner, James Mulick, Denis G. Sukhodolsky, Susan Williams, Naomi A. Swiezy, L. Eugene Arnold, Michael G. Aman, Lawrence Scahill, Kimberly A. Stigler, Christopher J. McDougle, Benedetto Vitiello, Tristram Smith. (2007) Development of a parent training program for children with pervasive developmental disorders. Behavioral Interventions 22:3, 201-221
CrossRef179
Joachim F. Hallmayer. (2007) Atypical antipsychotic medication in preschool children. Current Psychiatry Reports 9:3, 181-183
CrossRef180
Scott C. Flanders, Robert L. Findling, Eric A. Youngstrom, Gahan J. Pandina, Marcia F.T. Rupnow, Sarah E. Jensik, Gabrielle A. Carlson. (2007) Observed Clinical and Health Services Outcomes in Pediatric Inpatients Treated with Atypical Antipsychotics: 1999–2003. Journal of Child and Adolescent Psychopharmacology 17:3, 312-327
CrossRef181
B. Čabovska, S.L. Cox, A.A. Vinks. (2007) Determination of risperidone and enantiomers of 9-hydroxyrisperidone in plasma by LC-MS/MS. Journal of Chromatography B 852:1-2, 497-504
CrossRef182
James E. Carr, Linda A. LeBlanc. (2007) Autism Spectrum Disorders in Early Childhood: An Overview for Practicing Physicians. Primary Care: Clinics in Office Practice 34:2, 343-359
CrossRef183
Taylor Moran-Gates, Christopher Grady, Young Shik Park, Ross J. Baldessarini, Frank I. Tarazi. (2007) Effects of risperidone on dopamine receptor subtypes in developing rat brain. European Neuropsychopharmacology 17:6-7, 448-455
CrossRef184
Guillermo Montes, Jill S. Halterman. (2007) Bullying among Children with Autism and the Influence of Comorbidity with ADHD: A Population-Based Study. Ambulatory Pediatrics 7:3, 253-257
CrossRef185
Katsuhiko Nishimura, Kazuhiko Nakamura, A. Anitha, Kazuo Yamada, Masatsugu Tsujii, Yoshimi Iwayama, Eiji Hattori, Tomoko Toyota, Nori Takei, Taishi Miyachi, Yasuhide Iwata, Katsuaki Suzuki, Hideo Matsuzaki, Masayoshi Kawai, Yoshimoto Sekine, Kenji Tsuchiya, Gen-ichi Sugihara, Shiro Suda, Yasuomi Ouchi, Toshiro Sugiyama, Takeo Yoshikawa, Norio Mori. (2007) Genetic analyses of the brain-derived neurotrophic factor (BDNF) gene in autism. Biochemical and Biophysical Research Communications 356:1, 200-206
CrossRef186
Zinoviy A. Gutkovich, Gabrielle A. Carlson, Harold E. Carlson, Barbara Coffey, Natalie Wieland. (2007) Asperger's Disorder and Co-Morbid Bipolar Disorder: Diagnostic and Treatment Challenges. Journal of Child and Adolescent Psychopharmacology 17:2, 247-256
CrossRef187
John A. Schetz, David R. Sibley. 2007. Dopaminergic Neurotransmission. .
CrossRef188
Peter S. Jensen, Jan Buitelaar, Gahan J. Pandina, Carin Binder, Magali Haas. (2007) Management of psychiatric disorders in children and adolescents with atypical antipsychotics. European Child & Adolescent Psychiatry 16:2, 104-120
CrossRef189
PETER S. JENSEN, ERIC A. YOUNGSTROM, HANS STEINER, ROBERT L. FINDLING, ROGER E. MEYER, RICHARD P. MALONE, GABRIELLE A. CARLSON, EMIL F. COCCARO, MICHAEL G. AMAN, JAMES BLAIR, DONALD DOUGHERTY, CRAIG FERRIS, LAURIE FLYNN, EVELYN GREEN, KIMBERLY HOAGWOOD, JANICE HUTCHINSON, TOM LAUGHREN, LESLIE D. LEVE, DOUGLAS K. NOVINS, BENEDETTO VITIELLO. (2007) Consensus Report on Impulsive Aggression as a Symptom Across Diagnostic Categories in Child Psychiatry. Journal of the American Academy of Child & Adolescent Psychiatry 46:3, 309-322
CrossRef190
Gahan J. Pandina, Cynthia A. Bossie, Eriene Youssef, Young Zhu, Fiona Dunbar. (2007) Risperidone Improves Behavioral Symptoms in Children with Autism in a Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Autism and Developmental Disorders 37:2, 367-373
CrossRef191
Antonio Clavenna, Elisa Rossi, Marisa DeRosa, Maurizio Bonati. (2007) Use of psychotropic medications in Italian children and adolescents. European Journal of Pediatrics 166:4, 339-347
CrossRef192
Elaine Tierney, Michael Aman, David Stout, Krista Pappas, L. Eugene Arnold, Benedetto Vitiello, Lawrence Scahill, Christopher McDougle, James McCracken, Courtney Wheeler, Andres Martin, David Posey, Bhavik Shah. (2007) Parent satisfaction in a multi-site acute trial of risperidone in children with autism: a social validity study. Psychopharmacology 191:1, 149-157
CrossRef193
Christopher J. McDougle, John H. Krystal. (2007) Pediatric psychopharmacology: mood, anxiety and disruptive behavior/pervasive developmental disorders. Psychopharmacology 191:1, 1-3
CrossRef194
Benedetto Vitiello. (2007) Research in child and adolescent psychopharmacology: recent accomplishments and new challenges. Psychopharmacology 191:1, 5-13
CrossRef195
George M. Anderson, Lawrence Scahill, James T. McCracken, Christopher J. McDougle, Michael G. Aman, Elaine Tierney, L. Eugene Arnold, Andrés Martin, Liliya Katsovich, David J. Posey, Bhavik Shah, Benedetto Vitiello. (2007) Effects of Short- and Long-Term Risperidone Treatment on Prolactin Levels in Children with Autism. Biological Psychiatry 61:4, 545-550
CrossRef196
Pieter W. Troost, Bertine E. Lahuis, Mirjam H. Hermans, Jan K. Buitelaar, Herman van Engeland, Lawrence Scahill, Ruud B. Minderaa, Pieter J. Hoekstra. (2007) Prolactin Release in Children Treated With Risperidone. Journal of Clinical Psychopharmacology 27:1, 52-57
CrossRef197
G. Paul Amminger, Gregor E. Berger, Miriam R. Schäfer, Claudia Klier, Max H. Friedrich, Martha Feucht. (2007) Omega-3 Fatty Acids Supplementation in Children with Autism: A Double-blind Randomized, Placebo-controlled Pilot Study. Biological Psychiatry 61:4, 551-553
CrossRef198
David J. Posey, Michael G. Aman, James T. McCracken, Lawrence Scahill, Elaine Tierney, L. Eugene Arnold, Benedetto Vitiello, Shirley Z. Chuang, Mark Davies, Yaser Ramadan, Andrea N. Witwer, Naomi B. Swiezy, Pegeen Cronin, Bhavik Shah, Deirdre H. Carroll, Christopher Young, Courtney Wheeler, Christopher J. McDougle. (2007) Positive Effects of Methylphenidate on Inattention and Hyperactivity in Pervasive Developmental Disorders: An Analysis of Secondary Measures. Biological Psychiatry 61:4, 538-544
CrossRef199
Benedetto Vitiello, Ann Wagner. (2007) The Rapidly Expanding Field of Autism Research. Biological Psychiatry 61:4, 427-428
CrossRef200
Paul McNally, Fiona McNicholas, Paul Oslizlok. (2007) The QT interval and psychotropic medications in children. European Child & Adolescent Psychiatry 16:1, 33-47
CrossRef201
Ann Wagner, Luc Lecavalier, L. Eugene Arnold, Michael G. Aman, Lawrence Scahill, Kimberly A. Stigler, Cynthia R. Johnson, Christopher J. McDougle, Benedetto Vitiello. (2007) Developmental Disabilities Modification of the Children’s Global Assessment Scale. Biological Psychiatry 61:4, 504-511
CrossRef202
Ora S Jesner, Mehrnoosh Aref-Adib, Esther Coren, Chris Champion. 2007. Risperidone for autism spectrum disorder. .
CrossRef203
Philip Hazell. (2007) Drug therapy for attention-deficit/hyperactivity disorder-like symptoms in autistic disorder. Journal of Paediatrics and Child Health 43:1-2, 19-24
CrossRef204
Jud A. Staller. (2007) Psychopharmacologic treatment of aggressive preschoolers: A chart review. Progress in Neuro-Psychopharmacology and Biological Psychiatry 31:1, 131-135
CrossRef205
Benjamin Chavez, Mapy Chavez-Brown, Michael A Sopko, Jose A Rey. (2007) Atypical Antipsychotics in Children with Pervasive Developmental Disorders. Pediatric Drugs 9:4, 249-266
CrossRef206
Lesley J Scott, Sohita Dhillon. (2007) Risperidone. Pediatric Drugs 9:5, 343-354
CrossRef207
(2007) Parent training for children with pervasive developmental disorders: a multi-site feasibility trial. Behavioral Interventions 22:3, 179
CrossRef208
Nadia Chabane, Oliviesr Philippe. 2007. Les troubles envahissants du développement. , 263-273.
CrossRef209
Daniel Bailly. 2007. Le retard mental. , 274-288.
CrossRef210
Daniel Bailly. 2007. Les neuroleptiques. , 74-96.
CrossRef211
Pascal Lenoir, Joëlle Malvy, Chrystèle Bodier-Rethore. 2007. Thérapies. , 203-242.
CrossRef212
Thomas Günther, Beate Herpertz-Dahlmann, Jellemer Jolles, Kerstin Konrad. (2006) The Influence of Risperidone on Attentional Functions in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Co-Morbid Disruptive Behavior Disorder. Journal of Child and Adolescent Psychopharmacology 16:6, 725-735
CrossRef213
Iliyan Ivanov, Martha Klein, Wayne Hugo Green, Barbara Coffey. (2006) The Challenges of Psychopharmacological Management of Children with Severe Developmental Disabilities. Journal of Child and Adolescent Psychopharmacology 16:6, 793-799
CrossRef214
Stacey Wasserman, Rupa Iyengar, William F. Chaplin, Dryden Watner, Shulamit E. Waldoks, Evdokia Anagnostou, Latha Soorya, Eric Hollander. (2006) Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study. International Clinical Psychopharmacology 21:6, 363-367
CrossRef215
Elizabeth Stump. (2006) FDA APPROVAL OF RISPERIDONE GETS MIXED REVIEWS FROM AUTISM EXPERTS. Neurology Today 6:21, 23-24
CrossRef216
Elizabeth Stump. (2006) FDA APPROVAL OF RISPERIDONE GETS MIXED REVIEWS FROM AUTISM EXPERTS. Neurology Today 6:21, 23???24
CrossRef217
Joan Luby, Christine Mrakotsky, Melissa Meade Stalets, Andy Belden, Amy Heffelfinger, Meghan Williams, Edward Spitznagel. (2006) Risperidone in Preschool Children with Autistic Spectrum Disorders: An Investigation of Safety and Efficacy. Journal of Child and Adolescent Psychopharmacology 16:5, 575-587
CrossRef218
Maria R. Valicenti-McDermott, Howard Demb. (2006) Clinical Effects and Adverse Reactions of Off-Label Use of Aripiprazole in Children and Adolescents with Developmental Disabilities. Journal of Child and Adolescent Psychopharmacology 16:5, 549-560
CrossRef219
Ovsanna T. Leyfer, Susan E. Folstein, Susan Bacalman, Naomi O. Davis, Elena Dinh, Jubel Morgan, Helen Tager-Flusberg, Janet E. Lainhart. (2006) Comorbid Psychiatric Disorders in Children with Autism: Interview Development and Rates of Disorders. Journal of Autism and Developmental Disorders 36:7, 849-861
CrossRef220
David J. Posey, Ryan E. Wiegand, Jennifer Wilkerson, Melissa Maynard, Kimberly A. Stigler, Christopher J. McDougle. (2006) Open-Label Atomoxetine for Attention-Deficit/ Hyperactivity Disorder Symptoms Associated with High-Functioning Pervasive Developmental Disorders. Journal of Child and Adolescent Psychopharmacology 16:5, 599-610
CrossRef221
Rob Nicolson, Beth Craven-Thuss, Judy Smith. (2006) AProspective, Open-Label Trial of Galantamine in Autistic Disorder. Journal of Child and Adolescent Psychopharmacology 16:5, 621-629
CrossRef222
Helen H. L. Wong, Ronald G. Smith. (2006) Patterns of Complementary and Alternative Medical Therapy Use in Children Diagnosed with Autism Spectrum Disorders. Journal of Autism and Developmental Disorders 36:7, 901-909
CrossRef223
Elizabeth Berry-Kravis, Sue Ellen Krause, Sandra S. Block, Steve Guter, Joanne Wuu, Sue Leurgans, Penelope Decle, Kristina Potanos, Edwin Cook, Jeff Salt, Dominick Maino, Dahlia Weinberg, Rebecca Lara, Tristan Jardini, Jennifer Cogswell, Steven A. Johnson, Randi Hagerman. (2006) Effect of CX516, an AMPA-Modulating Compound, on Cognition and Behavior in Fragile X Syndrome: AControlled Trial. Journal of Child and Adolescent Psychopharmacology 16:5, 525-540
CrossRef224
Lawrence Scahill, Michael G. Aman, Christopher J. McDougle, James T. McCracken, Elaine Tierney, James Dziura, L. Eugene Arnold, David Posey, Christopher Young, Bhavik Shah, Jaswinder Ghuman, Louise Ritz, Benedetto Vitiello. (2006) AProspective Open Trial of Guanfacine in Children with Pervasive Developmental Disorders. Journal of Child and Adolescent Psychopharmacology 16:5, 589-598
CrossRef225
Suad Kapetanovic, George M Simpson. (2006) Review of antipsychotics in children and adolescents. Expert Opinion on Pharmacotherapy 7:14, 1871-1885
CrossRef226
Pieter W. Troost, Mark-Peter Steenhuis, Hanneke G. Tuynman-Qua, Luuk J. Kalverdijk, Jan K. Buitelaar, Ruud B. Minderaa, Pieter J. Hoekstra. (2006) Atomoxetine for Attention-Deficit/Hyperactivity Disorder Symptoms in Children with Pervasive Developmental Disorders: APilot Study. Journal of Child and Adolescent Psychopharmacology 16:5, 611-619
CrossRef227
Shauna P. Reinblatt, P. Karen Abanilla, Rahil Jummani, Barbara Coffey. (2006) Loxapine Treatment in an Autistic Child with Aggressive Behavior: Therapeutic Challenges. Journal of Child and Adolescent Psychopharmacology 16:5, 639-643
CrossRef228
Pieter W. Troost, Monika Althaus, Bertine E. Lahuis, Jan K. Buitelaar, Ruud B. Minderaa, Pieter J. Hoekstra. (2006) Neuropsychological Effects of Risperidone in Children with Pervasive Developmental Disorders: ABlinded Discontinuation Study. Journal of Child and Adolescent Psychopharmacology 16:5, 561-573
CrossRef229
John Peterson, Christopher Sheldon. (2006) Treating persistent adolescent aggression. Current Treatment Options in Neurology 8:5, 427-438
CrossRef230
LAWRENCE SCAHILL, CHRISTOPHER J. MCDOUGLE, SUSAN K. WILLIAMS, ANASTASIA DIMITROPOULOS, MICHAEL G. AMAN, JAMES T. MCCRACKEN, ELAINE TIERNEY, L. EUGENE ARNOLD, PEGEEN CRONIN, MARCO GRADOS, JASWINDER GHUMAN, KATHLEEN KOENIG, KRISTEN S.L. LAM, JAMES MCGOUGH, DAVID J. POSEY, LOUISE RITZ, NAOMI B. SWIEZY, BENEDETTO VITIELLO. (2006) Children's Yale-Brown Obsessive Compulsive Scale Modified for Pervasive Developmental Disorders. Journal of the American Academy of Child & Adolescent Psychiatry 45:9, 1114-1123
CrossRef231
Benjamin L. Handen, Richard Gilchrist. (2006) Practitioner Review: Psychopharmacology in children and adolescents with mental retardation. Journal of Child Psychology and Psychiatry 47:9, 871-882
CrossRef232
Jess P. Shatkin. (2006) Elucidating the Role of Risperidone in the Treatment of Disruptive Behavior Disorders. Journal of Child and Adolescent Psychopharmacology 16:4, 377-378
CrossRef233
Kirti Saxena, Kiki Chang, Hans Steiner. (2006) Treatment of aggression with risperidone in children and adolescents with bipolar disorder: a case series. Bipolar Disorders 8:4, 405-410
CrossRef234
Fred R Volkmar, Lisa A Wiesner, Alexander Westphal. (2006) Healthcare issues for children on the autism spectrum. Current Opinion in Psychiatry 19:4, 361-366
CrossRef235
Mani N. Pavuluri, David B. Henry, Julie A. Carbray, Gwen A. Sampson, Michael W. Naylor, Philip G. Janicak. (2006) AOne-Year Open-Label Trial of Risperidone Augmentation in Lithium Nonresponder Youth with Preschool-Onset Bipolar Disorder. Journal of Child and Adolescent Psychopharmacology 16:3, 336-350
CrossRef236
Wolfgang Aichhorn, W. Wolfgang Fleischhacker. (2006) Anwendungsgebiete neuerer Antipsychotika in der Behandlung von Kindern und Jugendlichen außerhalb des schizophrenen Spektrums. Psychiatrie und Psychotherapie 2:1, 23-28
CrossRef237
SUSAN K. WILLIAMS, LAWRENCE SCAHILL, BENEDETTO VITIELLO, MICHAEL G. AMAN, L. EUGENE ARNOLD, CHRISTOPHER J. MCDOUGLE, JAMES T. MCCRACKEN, ELAINE TIERNEY, LOUISE RITZ, DAVID J. POSEY, NAOMI B. SWIEZY, JILL HOLLWAY, PEGEEN CRONIN, JASWINDER GHUMAN, COURTNEY WHEELER, DOMENIC CICCHETTI, SARA SPARROW. (2006) Risperidone and Adaptive Behavior in Children With Autism. Journal of the American Academy of Child & Adolescent Psychiatry 45:4, 431-439
CrossRef238
FARAZ FARZIN, HAZEL PERRY, DAVID HESSL, DANUTA LOESCH, JONATHAN COHEN, SUSAN BACALMAN, LOUISE GANE, FLORA TASSONE, PAUL HAGERMAN, RANDI HAGERMAN. (2006) Autism Spectrum Disorders and Attention-Deficit/Hyperactivity Disorder in Boys with the Fragile X Premutation. Journal of Developmental & Behavioral Pediatrics 27:Supplement 2, S137-S144
CrossRef239
Pauline A. Filipek, Robin Steinberg-Epstein, Teri M. Book. (2006) Intervention for autistic spectrum disorders. NeuroRX 3:2, 207-216
CrossRef240
Lawrence Scahill, Gerald Erenberg, Cheston M. Berlin, Cathy Budman, Barbara J. Coffey, Joseph Jankovic, Louise Kiessling, Robert A. King, Roger Kurlan, Anthony Lang, Jonathan Mink, Tanya Murphy, Samual Zinner, John Walkup. (2006) Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRX 3:2, 192-206
CrossRef241
William O. Cooper, Patrick G. Arbogast, Hua Ding, Gerald B. Hickson, D. Catherine Fuchs, Wayne A. Ray. (2006) Trends in Prescribing of Antipsychotic Medications for US Children. Ambulatory Pediatrics 6:2, 79-83
CrossRef242
Eric Hollander, Erika Swanson, Evdokia Anagnostou, Ann Phillips, William Chaplin, Stacey Wasserman. (2006) Liquid Fluoxetine versus Placebo for Repetitive Behaviors in Childhood Autism. Progress in Neurotherapeutics and Neuropsychopharmacology 1:01, 105
CrossRef243
R. Canitano. (2006) Self injurious behavior in autism: clinical aspects and treatment with risperidone. Journal of Neural Transmission 113:3, 425-431
CrossRef244
Robert Milin, Jovan G. Simeon, Sue Batth, Smita Thatte, Glenda J. Dare, Selena Walker. (2006) An Open Trial of Olanzapine in Children and Adolescents With Asperger Disorder. Journal of Clinical Psychopharmacology 26:1, 90-92
CrossRef245
Pauline A. Filipek, Robin Steinberg-Epstein, Teri M. Book. (2006) Intervention for autistic spectrum disorders. Neurotherapeutics 3:2, 207
CrossRef246
2006. Neuroleptic drugs. , 2438-2489.
CrossRef247
Latha V. Soorya, Bryann R. Baker, Lisa Sharma, Eric Hollander. 2006. Obesity and Impulsive and Compulsive Disorders. , 145-164.
CrossRef248
Peter Paul De Deyn, Jan Buitelaar. (2006) Risperidone in the management of agitation and aggression associated with psychiatric disorders. European Psychiatry 21:1, 21-28
CrossRef249
Jessica A. Hellings, Jennifer R. Zarcone, R. Matthew Reese, Maria G. Valdovinos, Janet G. Marquis, Kandace K. Fleming, Stephen R. Schroeder. (2006) A Crossover Study of Risperidone in Children, Adolescents and Adults with Mental Retardation. Journal of Autism and Developmental Disorders 36:3, 401
CrossRef250
Lawrence Scahill, Gerald Erenberg, Cheston M. Berlin, Cathy Budman, Barbara J. Coffey, Joseph Jankovic, Louise Kiessling, Robert A. King, Roger Kurlan, Anthony Lang, Jonathan Mink, Tanya Murphy, Samual Zinner, John Walkup. (2006) Contemporary assessment and pharmacotherapy of Tourette syndrome. Neurotherapeutics 3:2, 192
CrossRef251
2006. Risperidone. , 3052-3068.
CrossRef252
Michael G. Aman, L. Eugene Arnold, M.D., Christopher J. McDougle, Benedetto Vitiello, Lawrence Scahill, Mark Davies, James T. McCracken, Elaine Tierney, Patricia L. Nash, David J. Posey, Shirley Chuang, Andres Martin, Bhavik Shah, Nilda M. Gonzalez, Naomi B. Swiezy, Louise Ritz, Kathleen Koenig, James McGough, Jaswinder K. Ghuman, Ronald L. Lindsay. (2005) Acute and Long-Term Safety and Tolerability of Risperidone in Children with Autism. Journal of Child and Adolescent Psychopharmacology 15:6, 869-884
CrossRef253
Benedetto Vitiello, Mark Davies, L. Eugene Arnold, Christopher J. McDougle, Michael Aman, James T. McCracken, Lawrence Scahill, Elaine Tierney, David J. Posey, Naomi B. Swiezy, Kathleen Koenig. (2005) Assessment of the Integrity of Study Blindness in a Pediatric Clinical Trial of Risperidone. Journal of Clinical Psychopharmacology 25:6, 565-569
CrossRef254
Catherine Lord, Ann Wagner, Sally Rogers, Peter Szatmari, Michael Aman, Tony Charman, Geraldine Dawson, V. Mark Durand, Lee Grossman, Donald Guthrie, Sandra Harris, Connie Kasari, Lee Marcus, Susan Murphy, Samuel Odom, Andrew Pickles, Lawrence Scahill, Evelyn Shaw, Bryna Siegel, Marian Sigman, Wendy Stone, Tristram Smith, Paul Yoder. (2005) Challenges in Evaluating Psychosocial Interventions for Autistic Spectrum Disorders. Journal of Autism and Developmental Disorders 35:6, 695-708
CrossRef255
Jessica A. Hellings, Jennifer R. Zarcone, Maria G. Valdovinos, R. Matthew Reese, Eric Gaughan, Stephen R. Schroeder. (2005) Risperidone-Induced Prolactin Elevation in a Prospective Study of Children, Adolescents, and Adults with Mental Retardation and Pervasive Developmental Disorders. Journal of Child and Adolescent Psychopharmacology 15:6, 885-892
CrossRef256
Pieter W. Troost, Bertine E. Lahuis, Mark-Peter Steenhuis, Cees E.J. Ketelaars, Jan K. Buitelaar, Herman van Engeland, Lawrence Scahill, Ruud B. Minderaa, Pieter J. Hoekstra. (2005) Long-Term Effects of Risperidone in Children With Autism Spectrum Disorders: A Placebo Discontinuation Study. Journal of the American Academy of Child & Adolescent Psychiatry 44:11, 1137-1144
CrossRef257
Craig A Erickson, Kimberly A Stigler, David J Posey, Christopher J McDougle. (2005) Risperidone in pervasive developmental disorders. Expert Review of Neurotherapeutics 5:6, 713-719
CrossRef258
J.-L. Goëb, M.-C. Mouren. (2005) Place des traitements psychotropes dans l'autisme de l'enfant et de l'adolescent. Annales Médico-psychologiques, revue psychiatrique 163:9, 791-801
CrossRef259
Jacqueline G Hugtenburg, Eibert R Heerdink, Yung Hwo Tso. (2005) Psychoactive drug prescribing by Dutch child and adolescent psychiatrists. Acta Paediatrica 94:10, 1484-1487
CrossRef260
G. Dumortier, B. Welniarz, C. Sauvebois, H. Medjdoub, H. Friche, N. Siad, K. Degrassat. (2005) Prescription des psychotropes en pédopsychiatrie : limites des indications officielles et perspectives thérapeutiques. L'Encéphale 31:4, 477-489
CrossRef261
Thomas W. McAllister. (2005) Risperidone for autistic disorder. Current Psychiatry Reports 7:5, 369-370
CrossRef262
Jessica A. Hellings, Marilyn Weckbaugh, Elizabeth J. Nickel, Sharon E. Cain, Jennifer R. Zarcone, R. Matthew Reese, Sandra Hall, David J. Ermer, Luke Y. Tsai, Stephen R. Schroeder, Edwin H. Cook. (2005) ADouble-Blind, Placebo-Controlled Study of Valproate for Aggression in Youth with Pervasive Developmental Disorders. Journal of Child and Adolescent Psychopharmacology 15:4, 682-692
CrossRef263
John C. LeBlanc, Carin E. Binder, Jorge L. Armenteros, Michael G. Aman, Jenny S. Wang, Huong Hew, Vivek Kusumakar. (2005) Risperidone reduces aggression in boys with a disruptive behaviour disorder and below average intelligence quotient: analysis of two placebo-controlled randomized trials. International Clinical Psychopharmacology 20:5, 275-283
CrossRef264
Andrea Witwer, Luc Lecavalier. (2005) Treatment Incidence and Patterns in Children and Adolescents with Autism Spectrum Disorders. Journal of Child and Adolescent Psychopharmacology 15:4, 671-681
CrossRef265
Christopher J. Kratochvil, Robert L. Findling, Christopher J. Mcdougle, Lawrence Scahill, Stephanie Hamarman, Christopher J. Kratochvil. (2005) Pharmacological Management of Agitation and Aggression in an Adolescent With Autism. Journal of the American Academy of Child & Adolescent Psychiatry 44:8, 829-832
CrossRef266
Jeff Q Bostic, Bryan H King. (2005) Autism spectrum disorders: emerging pharmacotherapy. Expert Opinion on Emerging Drugs 10:3, 521-536
CrossRef267
T CHARMAN. (2005) Autism spectrum disorders. Psychiatry 4:8, 81-84
CrossRef268
K Francis. (2005) Autism interventions: a critical update. Developmental Medicine & Child Neurology 47:7, 493-499
CrossRef269
Antonio Y. Hardan, Roger J. Jou, Benjamin L. Handen. (2005) Retrospective Study of Quetiapine in Children and Adolescents with Pervasive Developmental Disorders. Journal of Autism and Developmental Disorders 35:3, 387-391
CrossRef270
Nick C. Patel, M. Lynn Crismon, Kimberly Hoagwood, Michael T. Johnsrud, Karen L. Rascati, James P. Wilson, Peter S. Jensen. (2005) Trends in the Use of Typical and Atypical Antipsychotics in Children and Adolescents. Journal of the American Academy of Child & Adolescent Psychiatry 44:6, 548-556
CrossRef271
George T. Capone, Marco A. Grados, Walter E. Kaufmann, Susana Bernad-Ripoll, Amy Jewell. (2005) Down syndrome and comorbid autism-spectrum disorder: Characterization using the aberrant behavior checklist. American Journal of Medical Genetics Part A 134A:4, 373-380
CrossRef272
W. Victor R. Vieweg, Lisa J. Kuhnley, E. John Kuhnley, Emmanuel A. Anum, Bela Sood, Anand Pandurangi, Joel J. Silverman. (2005) Body mass index (BMI) in newly admitted child and adolescent psychiatric inpatients. Progress in Neuro-Psychopharmacology and Biological Psychiatry 29:4, 511-515
CrossRef273
Nick C. Patel, M. Lynn Crismon, Kimberly Hoagwood, Peter S. Jensen. (2005) Unanswered Questions Regarding Atypical Antipsychotic Use in Aggressive Children and Adolescents. Journal of Child and Adolescent Psychopharmacology 15:2, 270-284
CrossRef274
Christopher W. Bartlett, Neda Gharani, James H. Millonig, Linda M. Brzustowicz. (2005) Three autism candidate genes: a synthesis of human genetic analysis with other disciplines. International Journal of Developmental Neuroscience 23:2-3, 221-234
CrossRef275
Thomas Owley, Bennett Leventhal, Edwin H. Cook. (2005) EPS or Stereotypies?. Journal of Child and Adolescent Psychopharmacology 15:2, 150-151
CrossRef276
Susan E. Levy, Susan L. Hyman. (2005) Novel treatments for autistic spectrum disorders. Mental Retardation and Developmental Disabilities Research Reviews 11:2, 131-142
CrossRef277
Adrian Sandler. (2005) Placebo effects in developmental disabilities: Implications for research and practice. Mental Retardation and Developmental Disabilities Research Reviews 11:2, 164-170
CrossRef278
R CANITANO. (2005) Clinical experience with Topiramate to counteract neuroleptic induced weight gain in 10 individuals with autistic spectrum disorders. Brain and Development 27:3, 228-232
CrossRef279
George Bartzokis, Po H. Lu, Jana Turner, Jim Mintz, C. Scott Saunders. (2005) Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder. Biological Psychiatry 57:5, 474-479
CrossRef280
Benedetto Vitiello, Michael G. Aman, Lawrence Scahill, James T. McCracken, Christopher J. McDougle, Elaine Tierney, Mark Davies, L Eugene Arnold. (2005) Research Knowledge Among Parents of Children Participating in a Randomized Clinical Trial. Journal of the American Academy of Child & Adolescent Psychiatry 44:2, 145-149
CrossRef281
Michael G. Aman, Kristen S.L. Lam, Mary E. Van Bourgondien. (2005) Medication Patterns in Patients with Autism: Temporal, Regional, and Demographic Influences. Journal of Child and Adolescent Psychopharmacology 15:1, 116-126
CrossRef282
Robert L Rodnitzky. (2005) Drug-induced movement disorders in children and adolescents. Expert Opinion on Drug Safety 4:1, 91-102
CrossRef283
Susan L Santangelo, Katherine Tsatsanis. (2005) What is Known About Autism. American Journal of PharmacoGenomics 5:2, 71-92
CrossRef284
John W. Newcomer. (2005) Second-Generation (Atypical) Antipsychotics and Metabolic Effects. CNS Drugs 19:Supplement 1, 1???93
CrossRef285
Benjamin L. Handen, Martin Lubetsky. (2005) Pharmacotherapy in Autism and Related Disorders.. School Psychology Quarterly 20:2, 155-171
CrossRef286
Gabrielle A. Carlson. (2005) Early Onset Bipolar Disorder: Clinical and Research Considerations. Journal of Clinical Child & Adolescent Psychology 34:2, 333
CrossRef287
Richard P Malone, Silvia S Gratz, Mary Anne Delaney, Susan B Hyman. (2005) Advances in Drug Treatments for Children and Adolescents with Autism and Other Pervasive Developmental Disorders. CNS Drugs 19:11, 923-934
CrossRef288
Jacqueline Hugtenburg, Eibert Heerdink, Yung Hwo Tso. (2005) Psychoactive drug prescribing by Dutch child and adolescent psychiatrists. Acta Paediatrica 94:10, 1484
CrossRef289
W. V. R. Vieweg, A. B. Sood, A. Pandurangi, J. J. Silverman. (2005) Newer antipsychotic drugs and obesity in children and adolescents. How should we assess drug-associated weight gain?. Acta Psychiatrica Scandinavica 111:3, 177
CrossRef290
James W. Bodfish. (2004) Treating the core features of autism: Are we there yet?. Mental Retardation and Developmental Disabilities Research Reviews 10:4, 318-326
CrossRef291
LS Conwell, JA Batch. (2004) Oral glucose tolerance test in children and adolescents: Positives and pitfalls. Journal of Paediatrics and Child Health 40:11, 620-626
CrossRef292
(2004) Ask the Editor. Journal of Autism and Developmental Disorders 34:5, 593-594
CrossRef293
Jonathan B. Jensen. (2004) Conduct disorder and other disruptive behaviors: Pediatric psychopharmacology. Current Psychosis & Therapeutics Reports 2:3, 104-108
CrossRef294
K.M. Cornish, J. Turk, J. Wilding, V. Sudhalter, F. Munir, F. Kooy, R. Hagerman. (2004) Annotation: Deconstructing the attention deficit in fragile X syndrome: a developmental neuropsychological approach. Journal of Child Psychology and Psychiatry 45:6, 1042-1053
CrossRef295
Pinchen Yang, Jui-Hsiu Tsai. (2004) Occurrence of Priapism with Risperidone–Paroxetine Combination in an Autistic Child. Journal of Child and Adolescent Psychopharmacology 14:3, 342-343
CrossRef296
Emmeline Hazaray, Jason Ehret, David J. Posey, Theodore A. Petti, Christopher J. McDougle. (2004) Intramuscular Ziprasidone for Acute Agitation in Adolescents. Journal of Child and Adolescent Psychopharmacology 14:3, 464-470
CrossRef297
Kylie M Gray, Caroline Mohr. (2004) Mental health problems in children and adolescents with intellectual disability. Current Opinion in Psychiatry 17:5, 365-370
CrossRef298
Jennifer Cheng-Shannon, James J. McGough, Caroly Pataki, James T. McCracken. (2004) Second-Generation Antipsychotic Medications in Children and Adolescents. Journal of Child and Adolescent Psychopharmacology 14:3, 372-394
CrossRef299
Kimberly A. Stigler, David J. Posey, Christopher J. McDougle. (2004) Aripiprazole for Maladaptive Behavior in Pervasive Developmental Disorders. Journal of Child and Adolescent Psychopharmacology 14:3, 455-463
CrossRef300
Daniel J. Safer. (2004) A Comparison of Risperidone-Induced Weight Gain Across the Age Span. Journal of Clinical Psychopharmacology 24:4, 429-436
CrossRef301
Benedetto Vitiello, John H Heiligenstein, Mark A Riddle, Laurence L Greenhill, Jörg M Fegert. (2004) The interface between publicly funded and industry-funded research in pediatric psychopharmacology: opportunities for integration and collaboration. Biological Psychiatry 56:1, 3-9
CrossRef302
David J. Posey, Jessica I. Puntney, Teresa M. Sasher, Deborah L. Kem, Christopher J. McDougle. (2004) Guanfacine Treatment of Hyperactivity and Inattention in Pervasive Developmental Disorders: A Retrospective Analysis of 80 Cases. Journal of Child and Adolescent Psychopharmacology 14:2, 233-241
CrossRef303
Joseph Gonzalez-Heydrich, Gahan J. Pandina, Carl A. Fleisher, Olivia Hsin, Darcy Raches, Blaise F. Bourgeois, Joseph Biederman. (2004) No Seizure Exacerbation from Risperidone in Youth with Comorbid Epilepsy and Psychiatric Disorders: A Case Series. Journal of Child and Adolescent Psychopharmacology 14:2, 295-310
CrossRef304
EMMANUELLA AKANDE, KIRIAKOS XENITIDIS, SALLY MULLENDER, DENE ROBERSTON, JACK M. GORMAN. (2004) Autism or Schizophrenia: A Diagnostic Dilemma in Adults with Intellectual Disabilities. Journal of Psychiatric Practice 10:3, 190-195
CrossRef305
Roberto Tuchman. (2004) AEDs and psychotropic drugs in children with autism and epilepsy. Mental Retardation and Developmental Disabilities Research Reviews 10:2, 135-138
CrossRef306
George C Wagner, Nicole Avena, Taizo Kita, Toshikatsu Nakashima, Hans Fisher, Alycia K Halladay. (2004) Risperidone reduction of amphetamine-induced self-injurious behavior in mice. Neuropharmacology 46:5, 700-708
CrossRef307
Robert Gerlai, Julia Gerlai. (2004) Autism: a target of pharmacotherapies?. Drug Discovery Today 9:8, 366-374
CrossRef308
Purva H. Rawal, John S. Lyons, James C. MacIntyre, John C. Hunter. (2004) Regional variation and clinical indicators of antipsychotic use in residential treatment: A four-state comparison. The Journal of Behavioral Health Services & Research 31:2, 178-188
CrossRef309
Kenneth N. Sokolski, Aleksandra Chicz-Demet, Edward M. Demet. (2004) Selective Serotonin Reuptake Inhibitor-Related Extrapyramidal Symptoms in Autistic Children: A Case Series. Journal of Child and Adolescent Psychopharmacology 14:1, 143-147
CrossRef310
Antonella Gagliano, Eva Germanò, Giuseppina Pustorino, Caterina Impallomeni, Concetta D'Arrigo, Filippo Calamoneri, Edoardo Spina. (2004) Risperidone Treatment of Children with Autistic Disorder: Effectiveness, Tolerability, and Pharmacokinetic Implications. Journal of Child and Adolescent Psychopharmacology 14:1, 39-47
CrossRef311
Elizabeth Berry-Kravis, Kristina Potanos. (2004) Psychopharmacology in fragile X syndrome?Present and future. Mental Retardation and Developmental Disabilities Research Reviews 10:1, 42-48
CrossRef312
Ozgur Oner, Ayla Aysev, Ipek Kaplan. (2004) Possible Acute Confusional State After Risperidone in a Pediatric Patient. Journal of Child and Adolescent Psychopharmacology 14:3, 339
CrossRef313
Fred R. Volkmar, Catherine Lord, Anthony Bailey, Robert T. Schultz, Ami Klin. (2004) Autism and pervasive developmental disorders. Journal of Child Psychology and Psychiatry 45:1, 135-170
CrossRef314
Paz Toren, Sharon Ratner, Nathaniel Laor, Abraham Weizman. (2004) Benefit-Risk Assessment of Atypical Antipsychotics in the Treatment of Schizophrenia and Comorbid Disorders in Children and Adolescents. Drug Safety 27:14, 1135-1156
CrossRef315
Purva H. Rawal, John S. Lyons, James C. MacIntyre, John C. Hunter. (2004) Regional Variation and Clinical Indicators of Antipsychotic Use in Residential Treatment. The Journal of Behavioral Health Services & Research 31:2, 178-188
CrossRef316
M. G. Valdovinos, J. R. Zarcone, J. A. Hellings, G. Kim, S. R. Schroeder. (2004) Using the Diagnostic Assessment of the Severely Handicapped-II (DASH-II) to measure the therapeutic effects of risperidone. Journal of Intellectual Disability Research 48:1, 53-59
CrossRef317
André K. Ragnauth, Andrew Goodwillie, Cornelia Brewer, Louis J. Muglia, Donald W. Pfaff, Lee-Ming Kow. (2004) Vasopressin Stimulates Ventromedial Hypothalamic Neurons via Oxytocin Receptors in Oxytocin Gene Knockout Male and Female Mice. Neuroendocrinology 80:2, 92
CrossRef318
Kimberly A Stigler, Marc N Potenza, David J Posey, Christopher J McDougle. (2004) Weight Gain Associated with Atypical Antipsychotic Use in Children and Adolescents. Pediatric Drugs 6:1, 33-44
CrossRef319
JON M. McCELLAN, JOHN SCOTT Werry. (2003) Evidence-Based Treatments in Child and Adolescent Psychiatry: An Inventory. Journal of the American Academy of Child & Adolescent Psychiatry 42:12, 1388-1400
CrossRef320
ELLEN LEIBENLUFT, R JAMES R. BLAIR, DENNIS S. CHARNEY, DANIEL S. PINE. (2003) Irritability in Pediatric Mania and Other Childhood Psychopathology. Annals of the New York Academy of Sciences 1008:1, 201-218
CrossRef321
L Eugene Arnold, Benedetto Vitiello, CHRISTOPHER McDOUGLE, Larry Scahill, Bhavik Shah, Nilda M Gonzalez, Shirley Chuang, Mark Davies, Jill Hollway, Michael G Aman, Pegeen Cronin, Kathleen Koenig, Arlene E Kohn, DONALD J McMAHON, Elaine Tierney. (2003) Parent-Defined Target Symptoms Respond to Risperidone in RUPP Autism Study: Customer Approach to Clinical Trials. Journal of the American Academy of Child & Adolescent Psychiatry 42:12, 1443-1450
CrossRef322
Sanjoy Sathpathy, Bertrand Winsberg. (2003) Extrapyramidal Symptoms in Children on Atypical Antipsychotic Drugs. Journal of Clinical Psychopharmacology 23:6, 675-677
CrossRef323
Kimberly A. Stigler, David J. Posey, Christopher J. McDougle. (2003) Advances in the Pharmacotherapy of Pervasive Developmental Disorders (PDD). Child and Adolescent Psychopharmacology News 8:7, 6-11
CrossRef324
Robert A. Kowatch. (2003) A Double-Edged Sword: Atypical Antipsychotics in Child and Adolescent Psychiatry. Child and Adolescent Psychopharmacology News 8:7, 4-5
CrossRef325
Roberto Tuchman. (2003) Autism. Neurologic Clinics 21:4, 915-932
CrossRef326
David S. Janowsky, John E. Kraus, Jarrett Barnhill, Belal Elamir, John M. Davis. (2003) Effects of Topiramate on Aggressive, Self-Injurious, and Disruptive/Destructive Behaviors in the Intellectually Disabled: An Open-Label Retrospective Study. Journal of Clinical Psychopharmacology 23:5, 500-504
CrossRef327
Fred R Volkmar, David Pauls. (2003) Autism. The Lancet 362:9390, 1133-1141
CrossRef328
Agnieszka Bokszanska, Graham Martin, Mike Vanstraelen, Geraldine Holt, Nick Bouras, David Taylor. (2003) Risperidone and olanzapine in adults with intellectual disability: a clinical naturalistic study. International Clinical Psychopharmacology 18:5, 285-291
CrossRef329
Jan Blacher, Bonnie Kraemer, Monica Schalow. (2003) Asperger syndrome and high functioning autism: research concerns and emerging foci. Current Opinion in Psychiatry 16:5, 535-542
CrossRef330
Henry W.M. Kwok. (2003) Psychopharmacology in autism spectrum disorders. Current Opinion in Psychiatry 16:5, 529-534
CrossRef331
Julia Gerlai, Robert Gerlai. (2003) Autism: a large unmet medical need and a complex research problem. Physiology & Behavior 79:3, 461-470
CrossRef332
Rasim Somer Diler, Aysegul Yolga, Ayse Avci, Lawrence Scahill. (2003) Risperidone-Induced Obsessive-Compulsive Symptoms in Two Children. Journal of Child and Adolescent Psychopharmacology 13:supplement 1, 89-92
CrossRef333
Meraj Tajuddin, Satheesh K. Gangadharan. (2003) A Case Report of the Management of Behaviour Problems in Identical Twins with Rubenstein Taybi Syndrome. The British Journal of Development Disabilities 49:97, 111-116
CrossRef334
Erno A. van Schaick, Philippe Lechat, Bart M.M. Remmerie, Grant Ko, Kenneth C. Lasseter, Erik Mannaert. (2003) Pharmacokinetic comparison of fast-disintegrating and conventional tablet formulations of risperidone in healthy volunteers. Clinical Therapeutics 25:6, 1687-1699
CrossRef335
LAURENCE L. GREENHILL, BENEDETTO VITIELLO, MARK A. RIDDLE, PRUDENCE FISHER, ERIN SHOCKEY, JOHN S. MARCH, JEROME LEVINE, JANE FRIED, HOWARD ABIKOFF, JULIE M. ZITO. (2003) Review of Safety Assessment Methods Used in Pediatric Psychopharmacology. Journal of the American Academy of Child & Adolescent Psychiatry 42:6, 627-633
CrossRef336
Gabrielle A. Carlson, Peter S. Jensen, Robert L. Findling, Roger E. Meyer, Joseph Calabrese, Melissa P. DelBello, Graham Emslie, Laurie Flynn, Frederick Goodwin, Martha Hellander, Robert Kowatch, Vivek Kusumakar, Thomas Laughren, Ellen Leibenluft, James McCracken, Editha Nottelmann, Daniel Pine, Gary Sachs, David Shaffer, Renee Simar, Michael Strober, Elizabeth B. Weller, Janet Wozniak, Eric A. Youngstrom. (2003) Methodological Issues and Controversies in Clinical Trials with Child and Adolescent Patients with Bipolar Disorder: Report of a Consensus Conference. Journal of Child and Adolescent Psychopharmacology 13:1, 13-27
CrossRef337
Kimberly A. Stigler, David J. Posey, Christopher J. McDougle. (2003) Atypical Antipsychotics in Pediatric Psychiatry: Efficacy and Tolerability in Well-Designed Trials. Child and Adolescent Psychopharmacology News 8:1, 8-11
CrossRef338
Kenneth E Towbin. (2003) Strategies for pharmacologic treatment of high functioning autism and Asperger syndrome. Child and Adolescent Psychiatric Clinics of North America 12:1, 23-45
CrossRef339
Inge-Marie Eigsti, Theodore Shapiro. (2003) A systems neuroscience approach to autism: Biological, cognitive, and clinical perspectives. Mental Retardation and Developmental Disabilities Research Reviews 9:3, 206-216
CrossRef340
(2002) Risperidone in Children with Autism and Serious Behavioral Problems. New England Journal of Medicine 347:23, 1890-1891
Full Text341
(2002) Current Awareness in Human Psychopharmacology. Human Psychopharmacology: Clinical and Experimental 17:8, 435-444
CrossRef342
Kristen S. Langworthy-Lam, Michael G. Aman, Mary E. Van Bourgondien. (2002) Prevalence and Patterns of Use of Psychoactive Medicines in Individuals with Autism in the Autism Society of North Carolina. Journal of Child and Adolescent Psychopharmacology 12:4, 311-321
CrossRef343
CHRISTOPHER J. MCDOUGLE, DAVID POSEY, Paul J. Lombroso. (2002) Genetics of Childhood Disorders: XLIV. Autism, Part 3: Psychopharmacology of Autism. Journal of the American Academy of Child & Adolescent Psychiatry 41:11, 1380-1383
CrossRef344
Rapin, Isabelle, . (2002) The Autistic-Spectrum Disorders. New England Journal of Medicine 347:5, 302-303
Full Text345
&NA;. (2002) Risperidone reduces behavioural symptoms in autistic disorder. Inpharma Weekly &NA;:1350, 11
CrossRef
- Letters
